YAP and TAZ regulate adherens junction dynamics and endothelial cell distribution during vascular development

Short title: YAP /TAZ in vascular development

Filipa Neto¹,², Alexandra Klaus-Bergmann¹,³, Yu-Ting Ong⁴, Silvanus Alt¹, Anne-Clémence Vion¹,³, Anna Szymborska¹,³, Joana R. Carvalho⁵, Irene Hollfinger¹, Eireen Bartels-Klein¹,³, Cláudio A. Franco⁵, Michael Potente⁶,⁷, Holger Gerhardt¹,²,³,⁸,⁹,¹⁰

¹ Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Strasse 10, 13125 Berlin, Germany
² Vascular Biology Laboratory, London Research Institute – Cancer Research UK, Lincoln’s Inn Fields Laboratories, 44 Lincoln’s Inn Fields, WC2A 3LY London, United Kingdom
³ DZHK (German Center for Cardiovascular Research), partner site Berlin
⁴ Angiogenesis & Metabolism Laboratory, Max Planck Institute for Heart and Lung Research, 61231 Bad Nauheim, Germany
⁵ Vascular Morphogenesis Laboratory, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
⁶ International Institute of Molecular and Cell Biology, 02-109 Warsaw, Poland
⁷ DZHK (German Center for Cardiovascular Research), partner site Frankfurt Rhine-Main, 13347 Berlin, Germany
⁸ Vascular Patterning Laboratory, Vesalius Research Center, VIB, Leuven, Belgium
⁹ Vascular Patterning Laboratory, Vesalius Research Center, Department of Oncology, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium
¹⁰ Berlin Institute of Health (BIH), Berlin, Germany
*Co-corresponding author contact information

Professor Dr. Holger Gerhardt
Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Strasse 10, 13125 Berlin, Germany
E-mail: holger.gerhardt@mdc-berlin.de;
Tel: +49 (0)30 9406 1780; Fax: +49 (0)30 9406 1771.

Dr. Michael Potente
Max Plank Institute for Heart and Lung Research, Ludwigstr. 43, 61231 Bad Nauheim
E-mail: michael.potente@mpi-bn.mpg.de
Tel: +49 6032 705 11 07; Fax: +49 6032 705 11 04;

Keywords:
Endothelial cells, YAP, TAZ, VE-Cadherin, adherens junctions, vascular development, Notch, BMP.
Formation of blood vessel networks by sprouting angiogenesis is critical for tissue growth, homeostasis and regeneration. How endothelial cells arise in adequate numbers and arrange suitably to shape functional vascular networks is poorly understood. Here we show that YAP/TAZ promote stretch-induced proliferation and rearrangements of endothelial cells whilst preventing bleeding in developing vessels. Mechanistically, YAP/TAZ increase the turnover of VE-Cadherin and the formation of junction associated intermediate lamellipodia, promoting cell migration whilst maintaining barrier function. This is achieved in part by lowering BMP signalling. Consequently, the loss of YAP/TAZ in the mouse leads to stunted sprouting with local aggregation as well as scarcity of endothelial cells, branching irregularities and junction defects. Forced nuclear activity of TAZ instead drives hypersprouting and vascular hyperplasia. We propose a new model in which YAP/TAZ integrate mechanical signals with BMP signaling to maintain junctional compliance and integrity whilst balancing endothelial cell rearrangements in angiogenic vessels.
INTRODUCTION

A long-standing question in developmental and cell biology relates to how cells integrate mechanical and chemical signals to orchestrate the morphogenic behaviours that ensure adequate tissue patterning. During sprouting angiogenesis, the arrangement and distribution of cells rather than their numbers appear to drive morphogenesis of the vascular tree. Recent data showing unaltered remodelling in the absence of endothelial cell apoptosis and normal branching frequency across a range of endothelial cell densities support this idea (1). In the extreme, however, too few cells will jeopardize network formation and stability (2), whereas too many cells might compromise vessel calibre control (1).

Functional network formation therefore needs to establish the right number of cells in the right place, and distribute them such that the hierarchical branching pattern is supported. What establishes such a balance has remained unclear. Here we provide evidence for the yes-associated protein 1 (YAP) and its paralog WW domain containing transcription regulator 1 (TAZ) as critical endothelial cell autonomous regulators in this process.

YAP and TAZ, two transcriptional co-activators initially discovered as effectors of the Hippo signalling pathway, play a central role in organ size control via regulation of proliferation and apoptosis (3-5). In confluent cells, YAP and TAZ are phosphorylated by kinases of the Hippo pathway, which induces their retention in the cytoplasm. In sparse cells, YAP and TAZ can translocate to the nucleus, where they interact with transcription factors to regulate the expression of pro-proliferative and anti-apoptotic genes. Other stimuli have been found to regulate YAP and TAZ nuclear translocation and activity – these include, among others, G-protein coupled receptors (GPCRs) (6), junctional proteins (7, 8), and mechanical stimuli (9, 10). Furthermore, besides cell proliferation and apoptosis, YAP and TAZ also regulate cell differentiation (11), migration (12) and actomyosin contraction (13). In vascular development, the roles of YAP and TAZ are not fully understood. Yap null mutant zebrafish develop an initially normal vasculature but display increased vessel collapse and regression. Yap/Taz double mutant zebrafish die before the onset of circulation with severe developmental defects, precluding analysis of vascular development in this context (14). Endothelial-specific depletion of Yap in mice using the Tie2-Cre transgenic line is embryonically lethal due to heart valve defects caused by failed endothelial-to-mesenchymal transition (15). During post-natal development of the mouse retina, YAP was shown to regulate vascular branching and density by promoting the transcription of Angiopoetin-2 (16). While these studies point towards an important role for YAP in regulating blood vessel formation and maintenance, the cellular principles and effectors of YAP/TAZ in endothelial cells in vivo, as well as the possible interplay between YAP/TAZ and the major signalling pathways regulating angiogenesis remain poorly understood.
Here, we used loss and gain of function endothelial specific mouse models to address the roles of YAP and TAZ in the vasculature. We show that YAP and TAZ are both expressed and active in sprouting ECs and critical for sprouting angiogenesis. The inducible, endothelial-specific deletion of YAP and TAZ leads to severe morphogenic defects consistent with impaired junctional remodelling in vivo. We found that the loss of YAP and TAZ decreased VE-Cadherin turnover and decreased the frequency of junction associated intermediate lamellipodia. Furthermore, the loss of YAP and TAZ decreased cell migration and increased cell-cell coupling. We also discovered that endothelial YAP and TAZ strongly inhibit BMP signalling in vitro and in vivo, and that this is mechanistically linked to the migration and permeability defects. Together our results suggest that YAP and TAZ integrate mechanical stimuli with key transcriptional regulators of endothelial sprouting and cell rearrangements during angiogenesis.

RESULTS

YAP and TAZ have distinct expression patterns in endothelial cells of developing vessels and localise to the nucleus at the sprouting front. Immunofluorescence staining in the postnatal mouse retina showed that YAP and TAZ are distinctly expressed in the ECs of the developing vasculature (Figure 1). While YAP is evenly expressed throughout the vasculature (Figure 1 A-D), the expression of TAZ is especially prominent at the sprouting front (Figure 1 E-H). Furthermore, YAP is exclusively cytoplasmic in all areas of the retinal vasculature, with the exception of the sprouting front where some ECs express nuclear YAP, although at lower levels than in the cytoplasm. (Figure 1A'-D'). TAZ staining signal is very low in the remodelling plexus, arteries and veins (Figure1 E'-H'); at the sprouting front, TAZ is strongly nuclear in numerous ECs (Figure 1 E, green arrowheads and E'), and both nuclear and cytoplasmic in others (Figure 1E, red arrowheads). The nuclear signal of YAP and TAZ did not correlate with a tip or stalk cell phenotype; nuclear YAP and TAZ are rather present in a subset of tip and stalk ECs at the sprouting front. YAP and TAZ were also found at endothelial adherens junctions in veins and in the remodelling plexus, (yellow arrowheads in Fig. 1D' and F'), as revealed by co-staining for VE-Cadherin (Figure 1 – Figure supplement 1). Together, these observations suggest that YAP/TAZ are abundant proteins in the endothelium, which are dynamically regulated during the angiogenic process.

YAP/TAZ are required for vascular growth, branching and regularity of the network. To examine the cell-autonomous role of endothelial YAP and TAZ during angiogenesis we crossed mice
bearing floxed alleles of Yap or Taz (17) with mice expressing a tamoxifen-inducible Cre recombinase driven by the endothelial-restricted Pdgfb promoter (Pdgfb-iCreERT2) (18). Injection of the offspring with tamoxifen induced loss of YAP and TAZ protein in ECs during post-natal vascular development, as evidenced by immunofluorescence staining (Figure 2 – Figure supplement 1).

Endothelial deletion of YAP or TAZ led to mild vascular defects (Figure 2A,B,C,D). Yap\textsuperscript{fl/fl} Pdgfb-iCreERT2 mice (Yap\textsuperscript{iEC-KO}) presented reduced radial expansion of the vasculature (7% +/- 5.4 reduction, \(p=0.0123\)) and reduced vessel density (9% +/- 4.4 reduction, \(p=0.0002\)) (Figure 2G,H). Taz\textsuperscript{fl/fl} Pdgfb-iCreERT2 mice (Taz\textsuperscript{iEC-KO}) did not show altered radial expansion but displayed decreased vessel density (6% +/- 5.8 reduction, \(p=0.0214\)) (Figure 2H). Neither mutant showed a change in the branching frequency of vessels (Figure 2I). Interestingly, in Yap\textsuperscript{iEC-KO} retinas the expression of TAZ was increased and TAZ more often localised to the nucleus (Figure 2 – Figure supplement 2), suggesting compensatory regulation. Taz\textsuperscript{iEC-KO} retinas did not however show a clear difference in YAP expression (data not shown). Deleting both proteins in compound mutant mice (Yap\textsuperscript{fl/fl} Taz\textsuperscript{fl/fl} Pdgfb-iCreERT2, YapTaz\textsuperscript{iEC-KO}) led to a dramatic defect in blood vessel development (Figure 2E,F): the retinal vasculature showed a 21% (+/-14, \(p=0.0012\)) decrease in radial expansion (Figure 2G), a 26% (+/- 7.0, \(p<0.0001\)) decrease in capillary density (Figure 2H), and a 55% (+/- 15.4, \(p<0.0001\)) decrease in branching frequency (Figure 2I). Interestingly, the vessel loops were not only bigger in Yap/Taz\textsuperscript{iEC-KO} mice (Figure 2J), but also more variable in size (Figure 2K), and shape (Figure 2L) than in control mice. These results indicate that endothelial YAP and TAZ are critical for the development of a homogeneous blood vessel network and can perform redundant functions in the endothelium.

**YAP is required for endothelial cell proliferation in response to mechanical stretch.**

As YAP and TAZ display pro-proliferative and anti-apoptotic roles in many cell types (3, 4), we evaluated whether the reduced vascularization of Yap/Taz\textsuperscript{iEC-KO} retinas was associated with reduced cell proliferation or increased apoptosis. EC proliferation, assessed by EdU staining (Figure 3A-C), was decreased in Yap\textsuperscript{iEC-KO} retinas (23% +/- 10.0, \(p=0.0469\)), whilst not affected in Taz\textsuperscript{iEC-KO}. Consistent with our prior results the decrease in cell proliferation was strongest in Yap/Taz\textsuperscript{iEC-KO} mice (Figure 2J), but also more variable in size (Figure 2K), and shape (Figure 2L) than in control mice. Staining for cleaved caspase 3 revealed that apoptosis was unaffected by Yap/TAZ loss (Figure 3D-F).

To understand if YAP and TAZ were required for proliferation downstream of VEGF, we knocked down YAP and TAZ in human umbilical vein endothelial cells (HUVECs) using small interfering RNAs (siRNAs) (Figure 3 - Figure supplement 1) and measured the proliferation rate by flow cytometry after treatment with increasing concentrations of VEGF (Figure 3G). Interestingly, upon loss of YAP, TAZ or YAP/TAZ, ECs proliferated at similar or even increased rates compared to control cells.
Furthermore, VEGF treatment did not alter the subcellular localisation of YAP and TAZ in HUVECs (Figure 3 – Figure supplement 2), suggesting that VEGF is not a primary regulator of their activity.

We next asked whether YAP and TAZ mediate endothelial proliferation in response to stretch – another crucial mitogenic stimulus for the endothelium (19). To this end, we subjected HUVECs to 24h of stretch and measured the proliferation rate in comparison to non-stretched, static cells treated with the same siRNAs, by EdU labelling (Figure 3H). Control cells responded to stretch with a 5-fold average increase in proliferation, and this effect was reduced upon knockdown of VE-Cadherin confirming previous observations (19). The knockdown of YAP, but not of TAZ, led to a significant decrease in stretch-induced proliferation. The knockdown of YAP/TAZ showed a tendency to decreased proliferation in response to stretch but did not reach statistical significance. Thus YAP is required for endothelial cell proliferation in response to mechanical stimulation at cell-cell junctions.

**YAP/TAZ loss leads to irregular endothelial cell distribution and haemorrhages.**

Further analysis of Yap/Taz iEC-KO retinas revealed severe defects at the sprouting front. Yap/Taz iEC-KO mutant retinas had 23% (+/- 12.3, p= 0.0113) fewer angiogenic sprouts than the control (Figure 4A,B yellow asterisks and Figure 4 - Figure supplement 1). Moreover, whereas control sprouts were elongated and showed long cellular protrusions towards the non-vascularised front (Figure 4A'), sprouts in Yap/Taz iEC-KO retinas were rounder and lacked protrusions (Figure 4B'). The defective sprout morphology correlated with irregular spacing and frequent aggregations of ECs within the sprouts (Figure 4B'), arguing that migration and/or the rearrangement of ECs are perturbed in Yap/Taz mutant vessels. Additionally, the Yap/Taz iEC-KO vasculature displayed aberrant vessel crossings (Figure 4C,C',D,D',D''), suggesting that vessels may frequently have failed to anastomose or stabilize connections following sprouting, and instead passed each other. Interestingly, defects in cellular rearrangements, sprouting elongation and anastomosis have previously been associated with altered stability or dynamics of endothelial cell junctions (20-24). The defects in vessel morphology were coupled to defects in function as Yap/Taz iEC-KO retinas displayed large haemorrhages from sprouts at the angiogenic front (Figure 4E,E',F,F''), indicating loss of junctional integrity.

Together, these results argue against the cell proliferation defect being the sole driver of the Yap/Taz iEC-KO phenotype and suggest that endothelial YAP/TAZ play a role in the regulation of EC junctions.

**YAP/TAZ regulate adherens junction morphology and stability.**

Staining for VE-Cadherin revealed several junctional alterations in Yap/Taz iEC-KO vessels (Figure 4G-H). In control retinas, cell junctions were thin and mostly linear (Figure 4G'), while in Yap/Taz iEC-KO
retinas ECs displayed tortuous junctions (Figure 4H'). VE-Cadherin staining also unveiled profound differences in the arrangement of ECs within vessels. In control retinas, ECs were arranged into multicellular tubes, highlighted by the presence of two or more VE-Cadherin junctions running longitudinally along the axis of the vessels (Figure 4G,G'). Some unicellular segments lacking VE-Cadherin staining could also be found and always correlated with decreasing calibre, indicative of regressing vessels (Figure 4G red arrowheads) (25). In contrast, in Yap/Taz iEC-KO retinas we observed many unicellular vessel segments lacking longitudinal VE-Cadherin junctions, but in vessels of normal calibre (Figure 4H, red arrowheads and H''). As junctional remodelling has been shown to be required for the cellular rearrangements that establish multicellular tubes (20), these results suggest that YAP and TAZ regulate junctional remodelling.

VE-Cadherin staining in HUVECs after YAP, TAZ and YAP/TAZ knockdown further revealed altered junctional morphologies compared to control cells. Previous studies have correlated junctional morphology with cellular activities. In vivo, straight or linear junctions were associated with high Notch activity and stalk cell behaviour, while serrated junctions (also referred to as VE-Cadherin fingers) were found in tip cells or actively rearranging cells (21). In vitro, VE-Cadherin fingers were shown to steer migrating ECs and couple leader and follower cells (26), and have also been correlated with increased permeability in cell monolayers. More recently, junction associated intermediate lamellipodia (JAIL) have been identified in the sprouting vessels of the mouse retina, and linked to increased migration (27) as well as decreased permeability in cultured ECs (28).

To more accurately describe the differences in junctional morphology after YAP/TAZ knockdown, we defined five junctional categories: straight junctions, thick junctions, thick to reticular junctions, reticular junctions and fingers (Figure 5E). Live imaging analysis of VE-Cadherin-GFP transduced HUVECs showed that reticular junctions correspond to JAIL, and thick to reticular junctions to small JAIL. (Figure 5 - Supplementary video 1). Whereas control cells showed mostly reticular junctions (Figure 5A,F), the knockdown of YAP and TAZ led to an increase in straight junctions and fingers, respectively (Figure 5B,C,F). The combined knockdown of YAP/TAZ led to an increase in both straight junctions and fingers and to a loss of reticular junctions (Figure 5D,F). In addition, the knockdown of YAP/TAZ led to junctional breaks in the monolayer, as seen by the presence of gaps in VE-Cadherin stainings (Figure 5D, red arrowheads). Together, these observations demonstrate that YAP and TAZ together are required for the formation of JAIL and reduce the formation of straight junctions and fingers.

To understand whether this shift in morphology translated into a functional defect, we investigated the permeability of the monolayer to 250kDa dextran molecules. Only the combined
knockdown of YAP/TAZ led to a significant increase in permeability in comparison to the control situation (Figure 5G), suggesting that YAP/TAZ are both required for the barrier function of the endothelium and can compensate for each other in this particular role.

The dynamic rearrangements of ECs during sprouting require that cell-cell junctions are constantly assembled, rearranged and disassembled. To understand whether YAP and TAZ regulate the turnover of cell junctions, we pulse-labeled VE-Cadherin molecules at cell junctions using an antibody directly coupled to a fluorescent dye for 30 minutes (Figure 5H-I) (29). The antibody was subsequently washed out and cells cultured for two more hours in normal conditions, before being fixed and stained for surface VE-Cadherin using a second fluorescent label. Comparing the two sequential VE-cadherin labels allowed us to distinguish junctions with high, intermediate and low turnover rates (Figure 5J). In control cells, 44% of patches were of high turnover junctions, 24% of intermediate turnover junctions and 32% of low turnover junctions (Figure 5K). The knockdown of YAP/TAZ significantly decreased the percentage of high turnover junctions to 14% ($p=0.0387$) and increased the percentage of low turnover junctions to 58%. Interestingly, we found a correlation between the morphology of junctions and VE-Cadherin turnover rates (Figure 5L): straight junctions and fingers showed the lowest turnover rate, while reticular junctions showed the highest. To understand if the different VE-Cadherin turnover observed after knockdown of YAP/TAZ was caused by a shift in morphology, we compared the turnover of VE-Cadherin within the same morphological categories. Knockdown of YAP/TAZ decreased the percentage of high turnover junctions within all morphological categories, confirming a specific defect in VE-Cadherin turnover. To further investigate how YAP and TAZ affect the turnover of VE-cadherin, we transfected HUVECs with a photo-convertible fluorescent protein tagged VE-Cadherin (VE-cadherin-mEos3.2) and measured the fluorescence loss after photoconversion in straight junctions. The knockdown of YAP/TAZ led to a significant increase in the amount of immobile VE-cadherin-mEos3.2 at the junctions (Figure 5M) without significantly affecting the half time of fluorescence loss of the mobile fraction (Figure 5N). Together, these results show that YAP/TAZ increase the turnover of adherens junctions by increasing the pool of mobile VE-Cadherin.

Immunofluorescence staining for f-actin in YAP/TAZ deficient cells (Figure 5P, P’) showed an increase in actin bundles (actin filaments along the junction and stress fibers) and a decrease in branched actin networks, in comparison with control cells (Figure 5O, O’). This result correlates with the junctional morphologies observed before, as straight junctions and fingers associate respectively with actin filaments and stress fibers (30), while JAILs associate with branched actin (31). Interestingly, our VE-Cadherin pulse labeling experiments showed that the junction morphologies with less turnover, straight junctions and fingers, were the ones associated with bundled actin filaments, while the morphologies with higher turnover, reticular junctions, associated with branched actin networks.
As cell junctions and the actin cytoskeleton are essential for ECs to rearrange and migrate collectively (32), and Yap/Taz iEC-KO retinas presented less elongated sprouts suggestive of a migration defect, we asked whether cell migration was also regulated by YAP/TAZ.

**YAP/TAZ are required for individual endothelial cell migration.**

To address the requirement of YAP and TAZ for endothelial cell migration, we performed scratch-wound assays (Figure 6A-H). While in the control situation the wound was completely closed at 16h (Figure 6A,B,I), less than 50% of the wound area was closed after YAP knockdown at the same time point (\(p<0.0001\)) (Figure 6C,D,I). A stronger effect on endothelial cell migration was observed after the knockdown of TAZ and YAP/TAZ, with less than 20% of the wound area being closed (\(p<0.0001\) for siTAZ vs siCTR and for siYAP+siTAZ vs siCTR) (Figure 6E,F,G,H,I).

Given that cells aggregated at the sprouting front of Yap/Taz iEC-KO retinas, we wondered whether in addition to defective directional cell migration they also lacked the ability to shuffle with the neighbouring cells. Recent data illustrated that collectively migrating ECs in vitro move in streams and swirls and display straight junctions along the lateral boundaries and fingers along the front and rear (26). To investigate collective cell migration we therefore analysed the arrangement of cells in a confluent monolayer (Figure 6 J-O). Control cells displayed a cobblestone appearance without identifiable subgroups of cells (Figure 6J). In contrast, after knockdown of YAP/TAZ cells adopted elongated shapes and arranged into streams and swirls (Figure 6K). To quantify this effect we used the longest axis of the EC nucleus as a proxy for the orientation of each cell and developed a measure of monolayer coordination based on the alignment of cells with their neighbours (Figure 6L,L’,M,M’, N). A score of 1 would signify parallel alignment between all cells, and a score of 0 random alignment of the population. Control cells displayed higher than random alignment with their closest neighbours, but cells beyond 300\(\mu\)m from each other were arranged at random (Figure 6I). While the knockdown of YAP did not affect the alignment score of cells, the knockdown of TAZ led to increased alignment. The combined knockdown of YAP/TAZ led to an even higher degree of coordination, with higher alignment scores across all distances between cells. These results suggest that YAP/TAZ promote the ability of cells to distribute individually within monolayers.

**Nuclear YAP and TAZ inhibit Notch and BMP signalling in endothelial cells.**

To gain insight into the nuclear function of YAP and TAZ, we generated a Pdgfb-iCreERT2-inducible TAZ gain-of-function mouse allele, in which a mutated version of TAZ (TAZ S89A) is introduced in the Rosa26 locus and expressed by a CAG promoter following Cre-mediated excision of an upstream stop cassette (Figure 7 – Figure supplement 1). The serine-to-alanine mutation in TAZ results in enhanced...
nuclear TAZ localization as it escapes phosphorylation by the upstream Hippo kinase cascade (33). The allele also expresses nuclear EGFP by means of an IRES sequence, allowing the identification of recombined cells expressing the TAZ mutant protein. Taz iEC-GOF retinas exhibited 25% increased sprouting (+/- 12.2, $p=0.0074$) (Figure 7A,B yellow asterisks and Figure 7C) and 19% increased branching (+/- 8.3, $p=0.0012$) (Figure 7D). Thus, driving nuclear TAZ expression leads in many aspects to the opposite phenotype of Yap/Taz iEC-KO retinas, suggesting that the loss of the nuclear function of YAP/TAZ plays a key role in the development of the observed vascular loss-of-function phenotypes.

To elucidate the transcriptional targets of YAP and TAZ, we performed unbiased transcriptome analysis on HUVECs transduced with adenoviruses encoding for YAP and TAZ gain-of-function mutants or GFP as a control (AdYAP$^{S127A}$, AdTAZ$^{S89A}$, AdGFP) (Figure 7 – Figure supplement 2). Forced activation of YAP and TAZ led to congruent gene expression changes including the canonical YAP/TAZ target genes CYR61, ANKRD1, and CTGF, as expected. Interestingly, YAP and TAZ also suppressed numerous Notch and BMP target genes. During sprouting angiogenesis, Notch and BMP9/10 signalling restrict the acquisition of a tip cell phenotype by activated ECs (34-40). These results were confirmed by qRT-PCR analysis (Figure 7E): AdYAP$^{S127A}$ and AdTAZ$^{S89A}$ cells expressed significantly less LFNG, DLL4 and HES1 (Notch target genes), SMAD6, UNC5B and ID1 (BMP target genes) and HEY1 (a common Notch and BMP target gene) than control cells. Consistent with these findings, knockdown of YAP or TAZ lead to a substantial increase in Notch reporter activity (Figure 7 – Figure supplement 3A) and target gene expression (Figure 7F). Similar effects were observed for the BMP pathway (Figure 7 – Figure supplement 3B and Figure 7F), while TEAD-driven reporter activity and YAP/TAZ target genes were repressed (Figure 7 – Figure supplement 3C and Figure 7F).

To understand if Notch and BMP signalling were also affected in vivo, we stained Yap/Taz iEC-KO retinas for DLL4 and phospho-SMAD1/5/8. In control retinas, DLL4 expression was highest at the leading edge, decreasing over the first 100$\mu$m from the sprouting front, beyond which the expression was evenly low throughout the vessels in the plexus (Figure 7G,H and Figure 7 – Figure supplement 4). In Yap/Taz iEC-KO retinas the expression of DLL4 at the sprouting front was higher; additionally, the area of high DLL4 was broader, decreasing for up to 200$\mu$m from the sprouting front before flattening to the lower levels of the plexus. Moreover, staining Yap/Taz iEC-KO retinas for pSMAD1/5/8 showed a ~10 fold increase in the number of ECs positive for pSMAD1/5/8 at the sprouting front ($p<0.0001$) (Figure 7I,I',J,J',K).

Together, these results identify that endothelial YAP and TAZ repress Notch and BMP signalling during angiogenesis and retinal vascular expansion.
Inhibition of BMP signalling partially rescues the cellular defects of YAP/TAZ loss in endothelial cells.

To address whether the Notch or BMP signalling increase were responsible for the cellular defects of YAP/TAZ deficiency, we used different inhibitors to manipulate Notch and BMP signalling in cultured cells. Treatment with the Notch inhibitor DBZ corrected the Notch reporter activity increase after YAP and TAZ knockdown in HUVECs (Figure 8A), but did not affect the migration of cells in the scratch wound assay (Figure 8B).

To decrease BMP signalling we screened several inhibitors targeting different BMPs or BMP receptors (Figure 8C, Supplementary File 1). Only Ldn193187, an Alk2/3/1 kinase inhibitor, significantly decreased the BMP reporter activity after YAP and TAZ knockdown (p=0.0063) (Figure 8D). In comparison to control cells, the BMP reporter activity in YAP/TAZ deficient cells was 12 times higher, dropping to 7 times higher after Ldn193187 treatment. To understand if the partial BMP rescue altered the cellular defects after YAP/TAZ loss, we performed the scratch wound and permeability assays using this inhibitor. Ldn193187 treatment partially rescued the migration defect of YAP/TAZ knockdown HUVECs in the scratch wound assay, significantly increasing the wound closure at 16h from 33+/- 3% in DMSO treated cells to 56+/-5% in Ldn193187 treated cells (p=0.0022) (Figure 8E). Ldn193187 treatment fully rescued the permeability defect of YAP/TAZ knockdown HUVECs to 250kDa FITC dextran molecules (Figure 8F). Staining for VE-Cadherin further showed that Ldn193187 treatment decreased the frequency of finger junctions and increased the frequency of JAIL in YAP/TAZ deficient cells (Figure 8G-H). Quantification of junction morphologies identified that Ldn193187 treatment decreased the frequency of finger junctions in YAP/TAZ deficient cells to the levels found in control cells (Figure 8I and Figure 5F, % of fingers: siYAP/TAZ DMSO, 25+/-5%, siYAP/TAZ Ldn193187 12+/-0.6%, siCTR: 9+/-4%). Ldn193187 treatment also led to a 3-fold increase in thick to reticular junctions (p=0.012) and reticular junctions (p=0.043) in YAP/TAZ knockdown cells. The frequency of straight junctions was also significantly decreased (p=0.0326) although still remaining high in comparison to control cells. Together, these results show that the BMP signaling increase is at least partially involved in the cellular defects caused by YAP/TAZ deficiency.

To gain insight into how YAP and TAZ repress BMP signalling, we analysed the gene expression of BMPs, BMP receptors and co-receptors and BMP antagonists in YAP and TAZ gain of function mutant HUVECs (Figure 8 – Figure supplement 1). As YAP and TAZ function as transcriptional co-activators, the direct targets of YAP and TAZ would be upregulated in this assay, while genes that are downregulated would represent indirect regulation. Forced activation of YAP and TAZ led to increased expression of the BMP ligands BMP2, BMP4 and BMP6, which cannot explain the increase in BMP signalling in the loss of function condition. However, we also found increased expression of the
BMP antagonists \textit{FST, CTGF, BAMBI, SMURF2, NOG} and \textit{SMURF1}. Thus YAP and TAZ decrease BMP signalling in endothelial cells possibly by increasing the expression of BMP inhibitors.

Together, these results suggest that YAP/TAZ repress BMP activation in endothelial cells, modulating junctions and cell migration.

\section*{DISCUSSION}

The present study aimed to provide a detailed understanding of the distribution and function of endothelial YAP and TAZ in angiogenesis. Our finding that YAP and TAZ were present in the nucleus of ECs at the sprouting front of developing vessels shows parallels with other cell types where nuclear YAP and TAZ are detected in actively proliferating areas of developing tissues. Interestingly, however, YAP and TAZ show distinct expression patterns in ECs, although these proteins show a high degree of redundancy in many other cell types. While TAZ was predominantly expressed in the sprouting front where it accumulated strongly in endothelial nuclei, YAP was mostly cytoplasmic both in the sprouting front and also in more mature, remodelling vessels. Interestingly, recent work by Sakabe and colleagues showed that cytoplasmic YAP promotes endothelial cell migration (41).

In addition to nuclear and cytoplasmic YAP and TAZ, we also detected junctional localization of these proteins in retinal vessels. A previous study by Giampietro and colleagues (7) has shown that endothelial YAP associates with adherens junction proteins at stable junctions and that this prevents its nuclear accumulation and transcriptional activity. Whether this is also true for TAZ has previously not been addressed. A sequestration of YAP and TAZ either in the cytoplasm or bound to junctional proteins can potentially serve different and not necessarily mutually exclusive roles: preventing their nuclear activity, keeping a pool of protein ready to shuttle to the nucleus and drive gene expression, and having other cytoplasmic functions. It is not yet entirely clear what regulates the subcellular localization of YAP and TAZ in the developing vasculature. ECs at the sprouting front and in more mature vessels have different adherens junctions, experience distinct levels of signalling from secreted angiogenic molecules and are exposed to different levels of shear stress by blood flow. \textit{In vitro}, endothelial YAP and TAZ relocate to the nucleus upon disruption of cell junctions or loss of VE-Cadherin (shown for YAP by Choi and colleagues (16) and confirmed in our analysis also for TAZ, data not shown). In the mouse retina vasculature, Cao and colleagues (27) recently observed that endothelial cells at the sprouting front display reduced relative VE-Cadherin concentration that promotes cell-cell junction dynamics and JAIL formation. These observations nicely correlate with our own data showing the sprouting front as
the area of preferential nuclear YAP/TAZ. Furthermore, we did not find junctional localisation of
YAP/TAZ at the sprouting front, pointing to less sequestration of YAP/TAZ away from the nucleus by
more dynamics junctions. Together, these data provide additional strength to a model in which reduced
VE-Cadherin concentration at cell junctions may promote YAP and TAZ relocation to the nucleus. In
zebrafish, Nakajima and colleagues (14) showed that YAP nuclear relocation correlated with
lumenisation of sprouting vessels, and they attributed this to the effect of shear stress on YAP. In the
mouse retina, hemodynamic fluid laws predict that vessels at the sprouting front experience very low
levels of shear (42), arguing against YAP and TAZ being activated by shear in this model. Additionally,
we found no difference in the subcellular localisation of YAP or TAZ between arteries and veins, i.e.
vessels that experience distinct shear stress levels. However, it is possible that local and fast changes
in shear stress levels are more relevant to regulate YAP and TAZ than sustained shear. In support of
this idea, YAP and TAZ appear not to respond to 12 or 24h of laminar shear (43), but translocate to the
nucleus after only 10 minutes of laminar shear (14). Finally, although VEGF, a pro-angiogenic molecule
secreted by astrocytes at the avascular front, drives endothelial proliferation and migration, we found no
evidence for VEGF induced YAP and TAZ nuclear translocation, although others found opposite results
(44, 45). Other pro-angiogenic molecules, either locally produced or blood-borne, could regulate
endothelial YAP and TAZ during development; future work will help clarify these questions and how
different chemical and mechanical stimuli come together to regulate YAP and TAZ.

To address the cell autonomous role of YAP and TAZ we took advantage of an endothelial
specific inducible Cre to inactivate YAP and/or TAZ genetically during angiogenesis. The mild
phenotype of the single mutants in comparison to the drastic phenotype of the compound mutant
indicates functional redundancy in the endothelium. The compound loss of endothelial YAP and TAZ
leads in the mouse retina to a decrease in the radial expansion of vessels, vascular density, branching
and sprouting. This phenotype could be a consequence of a decreased number of ECs caused by a
proliferation defect (46). However, our further discovery that YAP and TAZ are required to establish
homogeneity in the plexus and prevent cellular aggregations suggests that endothelial YAP/TAZ
signalling is not only required to provide adequate numbers of cells but is also critically involved in
ensuring adequate EC distribution. We propose that endothelial YAP/TAZ operate in several
mechanisms that jointly establish a balance of the right number of endothelial cells in the right place.
First, endothelial YAP/TAZ drive proliferation in response to mechanical stimulation at the cell-cell
junction, and not in response to VEGF. We propose that in this way endothelial YAP/TAZ provide a cell
intrinsic mechanism of locally controlling cell densities, in contrast to growth factor-mediated cell
proliferation instructed by the surrounding tissue. Second, endothelial YAP/TAZ increase VE-Cadherin
turnover at cell-cell junctions, which we propose is essential for cells to migrate and rearrange while
maintaining the endothelial barrier at the same time. This corroborates recent findings in mouse hepatocytes where YAP antagonises adherens junction stability (47). The authors showed that YAP regulates hepatocyte adherens junctions in response to increased actomyosin contractility by increasing myosin II light chain gene expression. Accordingly, the transcriptional, nuclear role of YAP was required for junctional regulation. Together with our observations, these findings indicate the existence of a positive feedback loop where stable junctions sequester YAP and TAZ from the nucleus, therefore maintaining less junctional turnover, while remodelling junctions allow YAP and TAZ to relocate to the nucleus where they increase VE-Cadherin turnover. Our results also suggest that a high VE-Cadherin turnover at the sprouting front is required in order to maintain junctional integrity and prevent bleedings. YAP and TAZ increase the presence of JAIL (the more dynamic type of junction in our analysis) and promote branching of actin. These results are in accordance with recent data from Sakabe and colleagues reporting that YAP and TAZ increase Cdc42 activity in lamellipodia and phosphorylation of N-WASP (41), an actin binding protein that promotes branching of actin through the activation of the Arp2/3 complex.

Molecularly, how YAP and TAZ affect this complex cell behavior is not entirely clear. Our results identify that endothelial YAP/TAZ reduce the expression of Notch and BMP signaling in ECs, yet the in vitro rescue attempts show that the Notch increase is not the reason for the YAP/TAZ phenotype. This is further corroborated by in vivo data from Kim and colleagues showing that DAPT treatment fails to restore sprouting defects in YAP/TAZ mutant retinas (44). In contrast, reducing the increased BMP signalling experimentally corrected the permeability, and partially restored cell migration in YAP/TAZ deficient cells. This would suggest that BMP, not Notch, is a main driver of the observed cellular phenotypes. Whether the increased BMP signalling is also responsible for the phenotypes of YAP/TAZ loss of function in vivo remains to be shown. Furthermore, the full details of the involved ligands and receptors of the BMP pathway remain to be determined. Previous studies identified that BMP9/10 – Alk1 signalling is anti-angiogenic (39), while BMP2/4/6 - Alk2/Alk3 signalling is pro-angiogenic (48). Given the hyposprouting phenotype and reduced cell migration, we expected an increase in BMP9/10-Alk1 signalling after YAP/TAZ loss. However, the results from the panel of BMP inhibitors instead point towards a possible increase of the BMP2/4 – ALK3 pathway activity. However, given the notorious promiscuity of chemical inhibitors, and the different cellular context in which they are tested, this result should be seen as an indication at best. Further studies will need to address the nature of the BMP ligand/receptors and how the deregulated BMP signalling affects endothelial cell migration and adherens junctions in the context of YAP/TAZ deficiency.

Together, our results identify a role for YAP/TAZ in promoting endothelial cellular rearrangements through the regulation of junctional turnover and collectiveness of cell migration.
Conceptually, linking stretch-induced proliferation (to balance cell numbers) with modulation of junctional turnover (to facilitate cell rearrangements) seems ideally suited to achieve the required balance of cell distribution for functional vascular patterning.

MATERIAL AND METHODS

<table>
<thead>
<tr>
<th>Reagent type (species) or resource</th>
<th>Designation</th>
<th>Source or reference</th>
<th>Identifiers</th>
<th>Additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>strain, strain background (Mus musculus, C57BL/6J)</td>
<td>WT</td>
<td>The Jackson laboratories</td>
<td></td>
<td></td>
</tr>
<tr>
<td>genetic reagent (Mus musculus)</td>
<td>Yap iEC-KO, Yapi CreERT2</td>
<td>PMID: 27215660, PMID: 18257043</td>
<td></td>
<td></td>
</tr>
<tr>
<td>genetic reagent (Mus musculus)</td>
<td>Taz iEC-KO, TazPdgfb-CreERT2</td>
<td>PMID: 27215660, PMID: 18257043</td>
<td></td>
<td></td>
</tr>
<tr>
<td>genetic reagent (Mus musculus)</td>
<td>YapTaz iEC-KO, Yapi CreERT2 TazPdgfb-CreERT2</td>
<td>PMID: 27215660, PMID: 18257043</td>
<td></td>
<td></td>
</tr>
<tr>
<td>genetic reagent (Mus musculus)</td>
<td>Taz iEC-GOF, TAZS89AEGFP Pdgfb-CreERT2</td>
<td>This paper</td>
<td>Cloning information in Material and methods and Fig. 7–Fig. Supplem.1</td>
<td></td>
</tr>
<tr>
<td>cell line (human)</td>
<td>HUVEC</td>
<td>PromoCell and Lonza</td>
<td></td>
<td></td>
</tr>
<tr>
<td>transfected construct (human)</td>
<td>VE-Cadherin EGFP</td>
<td>PMID: 24658686</td>
<td></td>
<td></td>
</tr>
<tr>
<td>transfected construct (human)</td>
<td>VE-Cadherin mEos3.2</td>
<td>This paper</td>
<td>Cloning information in Material and methods</td>
<td></td>
</tr>
<tr>
<td>transfected construct (human)</td>
<td>pCMV-flag S127A YAP</td>
<td>Addgene, plasmid 27370</td>
<td></td>
<td></td>
</tr>
<tr>
<td>transfected construct (human)</td>
<td>3xFLAG-pCMV5-TOPO TA(S89A)</td>
<td>Addgene, plasmid 24815</td>
<td></td>
<td></td>
</tr>
<tr>
<td>transfected construct (human)</td>
<td>TEF-1 Luciferase reporter (GTIIC)</td>
<td>PMID: 15628970</td>
<td></td>
<td></td>
</tr>
<tr>
<td>transfected construct (murine)</td>
<td>RBPJ Luciferase reporter</td>
<td>PMID: 7569092</td>
<td></td>
<td></td>
</tr>
<tr>
<td>transfected construct (murine)</td>
<td>BRE Luciferase reporter</td>
<td>PMID: 11729207</td>
<td></td>
<td></td>
</tr>
<tr>
<td>transfected construct (human)</td>
<td>FOPflash Luciferase reporter</td>
<td>PMID: 9065401</td>
<td></td>
<td></td>
</tr>
<tr>
<td>transfected construct (Renilla)</td>
<td>Renilla Luciferase control reporter</td>
<td>Promega, E2241</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>Yap (rabbit polyclonal)</td>
<td>ThermoFisher Scientific, PA1-461894</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>Taz (rabbit polyclonal)</td>
<td>Sigma, HPA007415</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>Erg (goat polyclonal)</td>
<td>Santa Cruz Biotechnology, sc-18136</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>Erg (rabbit monoclonal)</td>
<td>Abcam, Ab92513</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>VE-Cadherin (rabbit polyclonal)</td>
<td>BD Biosciences, 555289</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>VE-Cadherin (goat polyclonal)</td>
<td>Santa Cruz Biotechnology, sc-6458</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>VE-Cadherin 55-7H1-Alexa-Fluor 647 Conjugate</td>
<td>BD Biosciences, 561567</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>TER-119 (rat monoclonal)</td>
<td>R&amp;D Systems, MAB1125</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>PECAM-1 (goat polyclonal)</td>
<td>R&amp;D Systems, AF3628</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>Cleaved caspase 3 (rabbit polyclonal)</td>
<td>R&amp;D Systems, AF835</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>Dll4 (goat polyclonal)</td>
<td>R&amp;D Systems, AF1389</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>pSMAD1/5/8 (rabbit monoclonal)</td>
<td>Cell Signalling, 13820S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>Phalloidin-Alexa Fluor 488</td>
<td>ThermoFisher Scientific, A12379</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>Ib4-Alexa Fluor 647 Conjugate</td>
<td>ThermoFisher Scientific, I32450</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>Ib4-Alexa Fluor 488 Conjugate</td>
<td>ThermoFisher Scientific, I21411</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>Ib4-Alexa Fluor 568 Conjugate</td>
<td>ThermoFisher Scientific, I21412</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>YAP 63.7 (mouse monoclonal)</td>
<td>Santa Cruz Biotechnology, sc-101199</td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody</td>
<td>GAPDH (mouse monoclonal)</td>
<td>Millipore, MAB374</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sequence-based reagent</td>
<td>SMART pool: siGENOME siRNA YAP</td>
<td>Dharmacon, M-012200-00-0005</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sequence-based reagent</td>
<td>SMART pool: siGENOME siRNA TAZ</td>
<td>Dharmacon, M-016083-00-0005</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sequence-based reagent</td>
<td>SMART pool: siGENOME siRNA VE-Cadherin</td>
<td>Dharmacon, M-003641-01-0005</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sequence-based reagent</td>
<td>SMART pool: siGENOME siRNA Non targeting 1</td>
<td>Dharmacon, D001206-13-05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sequence-based reagent</td>
<td>Taqman probes for RT-qPCR</td>
<td>Taqman</td>
<td></td>
<td></td>
</tr>
<tr>
<td>commercial assay or kit</td>
<td>Permeability assay - Transwell®</td>
<td>Costar, 3460</td>
<td></td>
<td></td>
</tr>
<tr>
<td>commercial assay or kit</td>
<td>Scratch wound assay - Culture-Insert 2 Well in μ-Dish 35 mm</td>
<td>Ibidi, 81176</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>------------------------------------------------------------</td>
<td>----------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>commercial assay or kit</td>
<td>Click-iT™ EdU Alexa Fluor™ 647 Imaging Kit</td>
<td>ThermoFisher Scientific, C10340</td>
<td></td>
<td></td>
</tr>
<tr>
<td>commercial assay or kit</td>
<td>Propidium Iodide (PI)/RNase Staining Solution</td>
<td>Cell Signalling, 4087</td>
<td></td>
<td></td>
</tr>
<tr>
<td>commercial assay or kit</td>
<td>M-MLV reverse transcriptase</td>
<td>ThermoFisher Scientific, 28025013</td>
<td></td>
<td></td>
</tr>
<tr>
<td>commercial assay or kit</td>
<td>RevertAid First Strand cDNA Synthesis Kit</td>
<td>ThermoFisher Scientific, K1621</td>
<td></td>
<td></td>
</tr>
<tr>
<td>commercial assay or kit</td>
<td>Agilent RNA 6000 Nano Kit</td>
<td>Agilent, 5067-1511</td>
<td></td>
<td></td>
</tr>
<tr>
<td>commercial assay or kit</td>
<td>GeneChip™ Human Gene 2.0 ST Array</td>
<td>ThermoFisher Scientific, 902113</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemical compound, drug</td>
<td>250kDa FITC Dextran</td>
<td>Sigma, FD250</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemical compound, drug</td>
<td>Lipofectamine 2000</td>
<td>ThermoFisher Scientific, 11668019</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemical compound, drug</td>
<td>Dharmafect 1 transfection reagent</td>
<td>Dharmacon, T-2001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemical compound, drug</td>
<td>Polybrene</td>
<td>Santa Cruz, sc-134220</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemical compound, drug</td>
<td>Hydroxytamoxifen</td>
<td>Sigma, 7904</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemical compound, drug</td>
<td>DBZ</td>
<td>Cayman chemicals 14627</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemical compound, drug</td>
<td>Recombinant-hGremlin</td>
<td>R&amp;D Systems, 5190-GR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemical compound, drug</td>
<td>Recombinant-hEndoglin</td>
<td>R&amp;D Systems, 1097-EN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemical compound, drug</td>
<td>LDN-193189</td>
<td>Cayman chemicals, 19396</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemical compound, drug</td>
<td>K02288</td>
<td>Cayman chemicals, 16678</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemical compound, drug</td>
<td>Recombinant hAlk1fc</td>
<td>R&amp;D Systems, 370-AL-100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemical compound, drug</td>
<td>VEGF-165 (murine)</td>
<td>Prepotech, 450-32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>software, algorithm</td>
<td>FIJI</td>
<td>FIJI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>software, algorithm</td>
<td>Cytoplasm to nucleus translocation assay</td>
<td>Cell Profiler, adapted from PMID: 17076895</td>
<td></td>
<td></td>
</tr>
<tr>
<td>software, algorithm</td>
<td>Mouse retina regularity script</td>
<td>This paper</td>
<td></td>
<td></td>
</tr>
<tr>
<td>software, algorithm</td>
<td>VE-Cadherin turnover analysis script</td>
<td>This paper</td>
<td></td>
<td></td>
</tr>
<tr>
<td>software, algorithm</td>
<td>Patching script</td>
<td>This paper</td>
<td></td>
<td></td>
</tr>
<tr>
<td>software, algorithm</td>
<td>Cell coordination analysis script</td>
<td>This paper</td>
<td></td>
<td></td>
</tr>
<tr>
<td>software, algorithm</td>
<td>Dll4 gradient analysis script</td>
<td>This paper</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Mice and treatments**
For loss of function experiments the following mouse strains were used: Yap\(^{fl/fl}\) and Taz\(^{fl/fl}\)\((17)\), Pdgfb-\(iCreERT2\)\((18)\). A detailed description of the knock-in mice overexpressing the TAZ gain-of-function allele will be provided elsewhere. Briefly, 3xFLAG-TAZ\(^{S89A}\)-IRES-nEGFP with a preceding floxed STOP cassette was knocked into the Rosa26 locus. Cre-mediated removal of the STOP sequence leads to CAG promoter-driven expression of 3xFLAG-tagged TAZ\(^{S89A}\) as well as of nuclear-localized enhanced green fluorescence protein (nEGFP). The allele was kept heterozygous in the experimental studies and was developed together with genOway.

Mice were maintained at the London Research Institute and at the Max Delbruck Center for Molecular Medicine (loss of function mice) and at the Max Planck Institute for Heart and Lung Research (gain of function mice) under standard husbandry conditions. To induce Cre-mediated recombination 4-hydroxytamoxifen (Sigma, 7904) was injected intraperitoneally (IP) (20 μL/g of 1 mg/mL solution) at postnatal day 1 and day 3 and eyes were collected at P6. In all loss and gain of function experiments control animals were littermate animals without Cre expression. Male and female mice were used for the analysis.

For endothelial cell proliferation assessment in the retina, mouse pups were injected IP 2 hours before culling with 20 uL/g of EdU solution (0.5 mg/mL; Thermo Fischer Scientific, C10340).

Cell culture
HUVECs from pooled donors (PromoCell) were cultured in EGM2-Bulletkit without antibiotics (Lonza) and used until passage 6. For YAP and TAZ gain of function experiments HUVECs were obtained from Lonza, cultured in endothelial basal medium (Lonza) supplemented with hydrocortisone (1 μg ml\(^{-1}\)), bovine brain extract (12 μg ml\(^{-1}\)), gentamicin (50 μg ml\(^{-1}\)), amphotericin B (50 ng ml\(^{-1}\)), epidermal growth factor (10 ng ml\(^{-1}\)) and 10% fetal bovine serum (Life Technologies) and used until passage 4. The manufacturers authenticated the identity of HUVECs by flow cytometry for cell-type specific markers (vWF, CD31, CD105) and by functional analysis (cells positive for acetylated low density lipoprotein uptake). All cells were tested negative for mycoplasma.

For knockdown experiments, HUVECs were transfected with SMARTpool: siGENOME siRNAs purchased from Dharmacon (Yap #M-012200-00-0005, Taz #M-016083-00-0005, VE-Cadherin #M-003641-01-0005 and non-targeting siRNA Pool 1 #D001206-13-05). Briefly, subconfluent (70-80%) HUVECs were transfected with 25 nM siRNA using Dharmafect 1 transfection reagent following the protocol from the manufacturer; transfection media was removed after 24h and experiments were routinely performed on the third day after transfection.

To activate YAP and TAZ signalling in ECs, FLAG-YAP\(^{S127A}\)- or 3x-FLAG-TAZ\(^{S89A}\)-encoding adenoviruses were generated in the adenoviral type 5 backbone lacking the E1/E3 genes (Vector...
Biolabs). GFP-encoding adenoviruses were used as a control. Infections were carried out by incubating sub-confluent HUVECs (70-80%) with starvation media (EBM containing 0.1% BSA) for 4 hours followed by the addition of adenoviral particles and polybrene (Santa Cruz). After 4 hours, HUVECs were washed with Hanks Buffer for at least five times and then cultured in complete EBM media with 10% FCS and supplements overnight. All experiments were performed 24 hours post transduction.

**Immunofluorescence staining**

To perform retina immunofluorescence, eyes were collected from postnatal day 6 mice and fixed in 4% PFA in PBS for 1h at 4C. Retinas were dissected in PBS and permeabilised/ blocked for 1h at room temperature in 1% BSA, 2% FBS, 0.5% Triton X100, 0.01% Na deoxycholate and 0.02% Na Azide in PBS. Primary and secondary antibodies were incubated overnight at 4C and for 2h at room temperature, respectively, both in 1:1 PBS: blocking buffer. Isolectin staining was performed overnight at 4C in Pblec after retinas were equilibrated for 1h in Pblec at room temperature. Retinas were post-stained fixed in 2% PFA in PBS for 10 minutes. To mount the samples Vectashield mounting medium. (Vector Labs, H1000) or ProLong Gold (Thermo Fisher Scientific) was used. Imaging was done by laser scanning confocal microscopy (Carl Zeiss LSM700, LSM780 and Leica TCS SP8). Processing of samples was carried out in tissues from littermates under the same conditions.

For immunofluorescence in HUVECs, cells were grown in #1.5 coverslips coated with poly-lysine and gelatin 0.2%. At the end of the experiment cells were fixed in 4% PFA for 10min, permeabilised in 0.3% Triton-X100 in blocking buffer for 5min and blocked in 1% BSA 20mM Glycine in PBS for 30 min. Primary and secondary antibodies were incubated for 2 and 1 hours, respectively, in blocking buffer. Nuclei labeling was performed by incubating cells with DAPI for 5 min (Life technologies, D1306).

A list of the primary antibodies used can be found in Supplementary File 2.

**Image analysis**

Analysis of radial expansion, capillary density, branching frequency, proliferating ECs, apoptosis and sprouting numbers was done using Fiji (49). Radial expansion corresponds to the mean distance from the optic nerve to the sprouting front (8 measurements in tilescans of two whole retinas per animal). Capillary density corresponds to the vessel area (measured by thresholding IB4 signal) divided by the field of view area (6–8 images of (425 μm)^2 between artery and vein per animal). Branching frequency was measured by manually counting all branching points in a field of view (4-5 images of (200 μm)^2 between artery and vein per animal). The plexus regularity was assessed through the standard deviation of the size and the circularity of the vascular loops in the plexus (using same images as for
analysis of capillary density). Vascular loops were segmented by thresholding the IB4 signal to avoid artifacts we excluded loops with a size smaller than 86 \( \mu m^2 \) for the analysis. Endothelial proliferation was measured by manually counting the number of EdU positive endothelial nuclei (ERG positive) and dividing by the vessel area (measured by thresholding IB4 signal) (4 images of (425 \( \mu m \))^2 containing the sprouting front and localized on top of arteries per animal). Apoptosis was measured manually by counting the number of cleaved caspase 3 positive figures and dividing by the vessel area (measured by thresholding IB4 signal) (tilescan of one whole retina per animal). The number of sprouts was measured manually (3 images of 425x850\( \mu m \) of the sprouting front per animal). To quantify DLL4 intensity the outline of the sprouting front and the position of the arteries were manually defined using IB4 staining. Vessels were segmented by thresholding the IB4 staining in Fiji. Then, DLL4 intensity inside the vasculature was normalised with the average DLL4 intensity outside of the vasculature. Subsequently, for every pixel inside the vasculature (excluding the arteries) the distance to the sprouting front was calculated. The normalised DLL4 values within each bin were averaged (15\( \mu m \) bins from 0 to 500 \( \mu m \)). For each retina quarter a curve was obtained, and the average and SEM of these curves was shown in the graph (one retina quarter was used per animal). To quantify pSMAD1/5/8 status the number of pSMAD1/5/8 positive endothelial nuclei was manually counted and dividing by the total number of endothelial nuclei (defined by being ERG positive) (3 images of (225\( \mu m \))^2 containing the sprouting front were used per animal).

To analyse YAP/TAZ subcellular localisation in HUVECs we adapted a previously existing cytoplasm-to-nucleus translocation assay pipeline from Cell Profiler (50). Briefly, YAP or TAZ staining intensity was measured both inside the nucleus of the cell and in a 12 pixels wide ring of cytoplasm grown radially from the nucleus. The nucleus localisation was determined using a DAPI mask.

Cell junction morphology analysis was done in confluent monolayers of HUVECs stained for VE-Cadherin. 5 morphological categories were defined: straight, thick, thick to reticular, reticular and fingers. We acquired 5 images of (160\( \mu m \))^2 per condition per experiment, divided each image in (16 \( \mu m \))^2 patches, and randomly grouped these patches. The classification into categories was done manually and blindly for the condition.

To analyse cell coordination we used confluent cells labelled for DAPI. The nuclei were automatically segmented using a customized Python algorithm relying on the Scikit Image Library. By fitting an ellipse to each nucleus we obtained its major and minor axis, and the angle of the major axis with the x-axis of the image was assigned to the nucleus as its orientation. This way each nucleus in the images was assigned a position given by its midpoint and an orientation. Next we analyzed the average alignment of the nuclei of two cells depending on their distance. As the nuclei don't have a directionality...
(i.e. they are nematics as opposed to vectors), the angles between two nuclei range from 0
corresponding to the nuclei being parallel, to $\pi/2$ corresponding to them spanning a right angle. For any
two cells in each image we calculated the angle and the Euclidean distance between them, and then we
binned the cells depending on their distance. We introduced a parameter called 'alignment' which is 1 if
all cells are perfectly aligned and 0 for a completely random distribution of cell orientations.

**Live imaging of VE-Cadherin-EGFP**

24h after siRNA transfection, knockdown HUVECs were transduced with VE-cadherin-EGFP adenovirus
as described before (21). Briefly, cells were incubated with the virus for 24 hours and then washed 3
times to remove viral particles. Cells were replated onto 2-well LabTek chambered coverslips (Nunc)
coated with 10 ug/mL Fibronectin (Sigma, F1141). Imaging was performed 48 hours post-transduction.
Cells were imaged at 37°C under 5% CO$_2$ on LSM 780 (Zeiss) using a Plan-Apochromat 63x/1.4 oil
objective. Images were acquired at a 260 sec time frame.

**VEGF treatment and YAP/TAZ staining**

Confluent HUVECs were maintained in VEGF free media for 24h. VEGF treatment was then performed
for 30 min, 1h and 3h with 0 or 40ng/mL of VEGF-165 (PrepoTech, 450-32). Immunofluorescence
staining and analysis of YAP and TAZ subcellular localisation was performed as above described.

**VEGF treatment and proliferation assessment**

Knockdown HUVECs were maintained in VEGF free media for 24h. VEGF treatment was then
performed for 24h with 0ng/mL, 40ng/mL, 200ng/mL or 1000ng/mL of VEGF-165. Cells were pelleted,
resuspended in 90% cold Methanol and stored at -20°C before further processing. Cells were then
resuspended in Propidium Iodide/RNase staining solution (Cell signaling, 4087) for 30 minutes before
cell cycle analysis by flow cytometry (LSRII, BD). Data was analysed using BD FACSDiva™ software.

**Mechanical stretch application and proliferation assessment**

HUVECs were plated on collagen I - 0.2% gelatine-coated Bioflex plates (BF-3001C, Flexcell
International Corporation). Gene knockdown was performed as previously described. Cells were
incubated in transfection media for 24h, and allowed to recover in fresh complete media for 4h.
Afterwards cells were incubated for 24h in serum starvation media (0.1%BSA in EBM2 pure media) to
form a confluent, quiescent monolayer. Cyclic stretch (0.25Hz, 15% elongation) was then applied for
24h using a Flexcell® FX-5000™ Tension System. Control cells were placed in the same incubator but
not on the Flexcell® device (static conditions). EdU pulsing was performed after 20h of the 24h stretch

22
period. At the end of the experiment cells were fixed in 4% PFA and EdU staining was performed according to the manufacturer’s protocol (Click-It EdU C10340 Life Technologies). Nuclei were labelled with DAPI. Three regions of interest were acquired per sample in a Carl Zeiss LSM700 scanning confocal microscopes (Zeiss, Germany). Quantification of proliferation was done using a CellProfiler pipeline. Percentage of S phase cells was determined as percentage of EdU positive nuclei over the total number of nuclei.

**Permeability assay**

24h after siRNA transfection cells were re-plated into fibronectin coated Transwell® membranes (Costar 3460) at confluence and incubated for 2 more days to stabilize cell junctions. On the third day after transfection 0.5mg/mL of 250kDa FITC Dextran in cell media (Sigma FD250) was added to the top well. Fluorescence on the bottom well was measured after 6h in a Gemini XPS fluorescent plate reader.

**Pulse chase VE-Cadherin experiment for quantification of low, intermediate and high turnover junctions**

Cells were labelled live with a non-blocking monoclonal antibody directed against extracellular VE-Cadherin and directly coupled with Alexa-Fluor647 (BD Pharmingen, #561567, 1:200) for 30 minutes. Cells were then washed 2x with PBS and incubated with complete media for additional 2 hours. Cells were fixed with 4% PFA and stained for VE-Cadherin (Santa Cruz Biotechnology, #6458, 1:200) with a secondary antibody coupled with Alexa-Fluor-488. 5 (160μm)² images per condition per experiment were acquired in a Carl Zeiss LSM700 confocal laser scanning microscope using the same acquisition settings. Max projection of z stack and merging of channels was done in Fiji. Images were divided in (16 μm)² patches and the patches were randomly grouped. Patches were classified into a morphological category and into low, intermediate or high turnover categories, manually and blindly for the condition.

**VE-cadherin mEos3.2 cloning**

mEos3.2 cDNA (51) was cloned downstream of full-length human VE-cadherin with a short linker (ARDPPV) and inserted into pAc-GFP-N1 backbone (Clontech) using NEBbuilder HiFi Assembly mix (NEB).

**Fluorescent loss after photoconversion experiments**

HUVECs double-transfected with YAP/TAZ or scrambled siRNAs and pN1-CMV-VE-cadherin-mEos3.2 were cultured to confluency in 2-well LabTek chambered coverslips (Nunc) coated with 10 ug/mL Fibronectin (Sigma, F1141) in EGM (Promocell) supplemented with EGM2 bulletkit (Lonza). Cells were
imaged at 37°C under 5% CO₂ on LSM 780 (Zeiss) equipped with Definite Focus stabilizer. Imaging was performed using the 488 nm (green mEos3.2 component) and the 561 nm (red component) lasers using Plan-Apochromat 63x/1.4 oil objective, 0.26 x 0.26 μm pixel size and 5.09 μs pixel dwell time, 16-bit image depth. A circular region of interest (ROI) of 21 μm² area was selected on straight junctions and photoconverted using the 405 nm laser. Mean fluorescence intensity in the ROI was monitored in the red channel for 15 min with 10s resolution, while the movement of the junction was followed in the green channel.

Background signal in each frame was estimated by measuring mean intensity in non-photoconverted region and subtracted from the fluorescence-loss curves. The curves were further corrected for bleaching, using parameters estimated from fixed cells. The curves were normalized between the mean intensity in the frames before photoconversion and fluorescence intensity measured immediately after photoconversion. Normalized curves were smoothed using the moving average method; the half-time of redistribution and immobile fraction of VE-cadherin were estimated directly from the plots. Only junctions which did not substantially move or remodel during the observation time were considered for analysis.

Analysis was performed using Fiji and Matlab (Mathworks).

**Scratch wound assay**

24h after siRNA transfection cells were re-plated into a scratch wound assay device (IBIDI). On the following day a cell free gap of 500μm was created by removing the insert of the device. Images were taken immediately after removing the insert (0h) and after 16h. The cell free area was measured in Fiji and used to calculate the percentage of wound closure at 16h.

**RNA extraction and quantitative real time-polymerase chain reaction**

RNA was extracted using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. For HUVECs transfected with adenoviruses carrying YAP and TAZ gain of function mutations, 2μg of total RNA were reverse transcribed to cDNA using M-MLV reverse transcriptase (ThermoFisher Scientific). For HUVECs transfected with siRNAs 90ng of RNA were reverse transcribed using RevertAid First Strand cDNA Synthesis Kit (ThermoFisher Scientific). qRT-PCR was performed using TaqMan reagents and probes (Applied Biosystems) (listed in Supplementary File 3). qRT-PCR reactions were run on a StepOnePlus real-time PCR instrument (ThermoFisher Scientific) or Quant Studio 6 Flex (Applied Biosystems) and expression levels were normalised to human ACTB or human HPRT1 using the 2deltaCT method.

**Western blot**
Protein was extracted from HUVECs using M-PER protein extraction reagent with Halt Protease and Phosphatase inhibitors (Pierce). Proteins concentration was assessed using a BCA protein assay kit (Pierce). Proteins were separated by SDS–PAGE and blotted onto nitrocellulose membranes (Bio-Rad). Membranes were probed with specific primary antibodies and then with peroxidase-conjugated secondary antibodies. The following antibodies were used: YAP 63.7 (Santa Cruz Biotechnology, sc-101199, 1:1000), GAPDH (Millipore, MAB374, 1:4000). The bands were visualized by chemiluminescence using an ECL detection kit (GE Heathcare) and a My ECL Imager (Thermo Scientific).

Dual luciferase reporter assay
Renilla-luciferase reporter assays for TEF-1 (52), RBPj (53), BRE (54, 55) and FOPflash (56)-Luciferase promoter activity were performed as follows: 48 hours after gene knockdown by siRNA HUVECs were cotransfected with 600 ng of Luciferase reporter gene construct and 300 ng of pRL-TK (Promega) using Lipofectamine2000 and incubated for 4 hours. Cell extracts were prepared 72 hours post siRNA transfection and 24 hours post Luciferase reporter transfection, and luciferase activity was measured using a dual luciferase system as described (57). Experiments were carried out in duplicates and results were normalized to the correspondent FOPflash/Renilla measurement.

Microarray and gene set enrichment analysis
Microarray studies were performed as described (58). In brief, total RNA was extracted from HUVECs using the RNeasy kit (Qiagen) and RNA quality assessed with the 6000 nano kit and an Agilent Bioanalyser. RNA was labelled according to the Affymetrix Whole Transcript Sense Target Labeling protocol. Affymetrix GeneChip® Human Gene 2.0 ST arrays were hybridized and scanned using Affymetrix protocols. Data were analysed using the Affymetrix expression console using the RMA algorithm; statistical analysis was done using DNASTar Arraystar 11. Heat maps of gene signatures were plotted using RStudio, Inc.

Notch and BMP inhibition experiments
A list of the reagents used, together with duration of treatment, can be found in Supplementary File 1.

Statistical Analysis
Statistical analyses were performed using GraphPad Prism software and p value was determined using unpaired Student t-test between the control and the knockout/ knockdown/ gain of function condition. Statistical significance was considered for p<0.05. Values shown are mean and standard deviation was
used as the dispersion measure. Biological replicates refer to individual mice for *in vivo* experiments and
different wells for *in vitro* cell culture experiments; independent experiments refer to experiments done in
different days; technical replicates refer to repeated measurements taken from the same sample, both
for *in vivo* and *in vitro*. Exclusion of outliers was done using “Robust regression and Outlier removal”
from GraphPad Prism software, with a coefficient Q of 1%. A statistical method of sample size
calculation was not used during study design. For *in vivo* experiments, we used an average of 6 animals
per experiment, from different litters, with a minimum of 3 (detailed number of animals used in figure
legends and source data). For *in vitro* experiments, we did a minimum of 3 independent experiments
(detailed number of experiments in figure legends and source data). When technically possible the
investigators were blind to the genotype of the animal or cell culture condition during sample processing
and data analysis.
Acknowledgments

We thank members of the Vascular Biology (Berlin) and Vascular Patterning (VIB – Leuven) Laboratories for helpful discussions. We thank the Cancer Research UK - London Research Institute and the Max Delbrück Center for Molecular Medicine Animal Facilities for animal care and technical support. We thank Dr. Axel Behrens for kindly providing the Taz$^{fl/fl}$ mice. We thank Dr. Walter Birchmeier and Dr. Daniel Besser for providing the Normalizer and BRE-luc reporter, Dr. Eric Sahai and Dr. Nic Tapon for providing the TEF1-reporter, and Dr. Michael Gotthardt and Dr. Michael Radke for access to the Flexcell® Tension System and technical assistance. We thank Dr. Dietmar Vestweber for providing the VE-Cadherin-EGFP adenovirus. We specially thank Dr. Veronique Gebala, Dr. Andre Rosa and Dr. Baptiste Coxam for helpful comments on the manuscript.

FN was financially supported by the Fundação para a Ciência e a Tecnologia (FCT), CRUK-CRICK and the MDC. ACV, AKB and EBK were supported by the DZHK (German Centre for Cardiovascular Research), AS was supported by the EMBO (European Molecular Biology Organization), JRC was supported by the FCT. CAF is supported by the FCT, EC-ERC Starting Grant, Portugal2020 program. MP is supported by the Max Planck Society, the ERC Starting Grant ANGIOMET, the Deutsche Forschungsgemeinschaft, the Excellence Cluster Cardiopulmonary System, the LOEWE grant Ub-Net, the DZHK, the Stiftung Charité and the EMBO Young Investigator Program. HG is supported by the DZHK and ERC Consolidator Grant Reshape 311719.

Competing interests
None.


Figure 1. YAP and TAZ are expressed throughout the vasculature of developing mouse retinas, and localise to the nucleus of sprouting endothelial cells.

Immunofluorescence staining of YAP (green, A-D and A’-D’) and TAZ (green, E-H and E’-H’) was performed in wild-type mouse retinas at post-natal day 6 (P6). Retinas were co-stained with the endothelial membrane marker Isolectin-B4 (IB4; blue) and with antibodies against the endothelial nuclei marker ERG (red). White dotted lines, outline of endothelial nuclei. Yellow dotted lines, outline of perivascular cells’ nuclei. Green arrowheads, nuclear localisation of YAP and TAZ. Red arrowheads, cytoplasmic localisation of YAP and TAZ. Yellow arrowheads, junctional localisation of YAP and TAZ. Images correspond to single confocal planes. n>3 animals for each staining. Scale bar: 10μm.

Figure 1 - Figure supplement 1. YAP and TAZ localise at endothelial adherens junctions in the mouse retina.

Immunofluorescence stainings of YAP (green, A-C,A’-C’), TAZ (green, D-F, D’-F’) and VE-Cadherin (red, B,E,B’,E’) were performed in wild-type mouse retinas at P6. Arrows, co-localisation of YAP or TAZ with VE-Cadherin. Images correspond to single confocal planes. n> 3 pups per staining. Scale bar A-C and D-F 10μm, A’-C’ and D’-F’ 3μm.

Figure 2 – Endothelial YAP and TAZ are required for vessel growth, branching and homogeneity of the plexus.

A-F, Retinas from P6 Yap iEC-KO (B), Taz iEC-KO (D) and YapTaz iEC-KO (F), and respective control pups (A,C,E) were stained with Isolectin B4 (IB4). Scale bar: 200μm.

G-J, Quantification of radial expansion (G), vessel density (H), branching frequency (I) and area of vessel loops (J) in Yap iEC-KO, Taz iEC-KO and YapTaz iEC-KO. Results are shown as percentage of the respective controls. Data are mean +/- SD. n≥ 5 pups. p values were calculated using unpaired t-test. *, p<0.05; **, p<0.01; ****, p<0.0001.

K, L, Quantification of the standard deviation of the area (K) and circularity (L) of the vessels loops in Yap iEC-KO, Taz iEC-KO and YapTaz iEC-KO retinas. Results are shown as percentage of the respective controls. Data are mean +/- SD. n≥ 5 pups. p values were calculated using unpaired t-test. *, p<0.05; **, p<0.01; *** , p<0.001****, p<0.0001

Figure 2 – Figure supplement 1. YAP and TAZ proteins are lost upon Cre-mediated genetic deletion in P6 mouse retinas.

Yap iEC-KO (Yap^{fl/fl} Pdgfb-iCreERT2+/wt), Taz iEC-KO (Taz^{fl/fl} Pdgfb-iCreERT2+/wt) and respective littermate control mice (YapControl, Yap^{fl/fl} and TazControl, Taz^{fl/fl}) were injected with tamoxifen at P1
and P3. At P6, mouse retinas were stained for YAP (grey, B,D), TAZ (grey, F,H), and with Isolectin B4 (IB4; red, A,C,E,G). n> 3 pups. Scale bar: 20μm.

**Figure 2 – Figure supplement 2. TAZ compensates for the loss of YAP in endothelial cells in vivo.**

Retinas from P6 Yap iEC-KO (B,D and B',D') and littermate controls (A,C and A', C') were immunostained for TAZ. Green arrowheads, nuclear Taz. A,B, A',B' images correspond to maximum projection of z stack. C,D,C',D' correspond to single confocal planes. n> 3 pups. Scale bar: A-D 50μm, A'-D' 20μm

**Figure 3. YAP and TAZ are required for endothelial cell proliferation in vivo and endothelial cell proliferation in response to mechanical stretch in vitro.**

A, B, P6 retinal vessels labelled with IB4 (grey) and stained for EdU (red, marking S phase positive cells) and Erg (green, marking endothelial nuclei) in YapTaz iEC-KO (B) and littermate control mice (A). A',B', mask of Erg + cells indicating endothelial nuclei. A'', B'', mask of Erg + and EdU + cells indicating proliferating endothelial cells. C, Quantification of endothelial proliferation in Yap iEC-KO (n=3 control/4 KO pups), Taz iEC-KO (n=5 control/5 KO pups) and YapTaz iEC-KO (n=8 control/7 KO pups). Number of EdU-positive and ERG-positive cells per IB4 labelled vascular area was calculated for each genotype and results are shown in percentage of the respective controls. Data are mean +/- SD. p values were calculated using unpaired t-test. ns, p>0.05; *, p<0.05; **, p<0.01. Scale bar: 50μm.

D, E, P6 retinal vessels labelled with IB4 (grey) and stained for cleaved caspase 3 (red) in YapTaz iEC-KO (E) and littermate control mice (D).D', E', magnification of boxed area in D,E. Red arrowheads, cleaved caspase 3 positive endothelial cell. Black arrowheads, cleaved caspase 3 outside vessels. D'',E'', mask of cleaved caspase 3 positive endothelial cells. F, quantification of endothelial apoptosis in Yap iEC-KO (n=7 control/7 KO pups), Taz iEC-KO (n= 4 control/4KO pups) and YapTaz iEC-KO (n=5 control/4 KO pups). Data are mean +/- SD. p values were calculated using unpaired t-test. ns, p>0.05. Scale bar: D-E 100μm, D'-E' 50μm.

G, Quantification of endothelial proliferation with increasing concentrations of VEGF treatment in YAP, TAZ and YAP/TAZ knockdown cells and control. HUVECs were treated with 0, 40, 200 or 1000 ng/mL VEGF for 24h and the percentage of cells in S phase was determined by flow cytometry. Graph shows the mean + SD fold change in percentage of S phase positive cells relative to 0 ng/mL of VEGF treatment. n= 3 independent experiments; > 50.000 cells analysed per experiment per condition.

**H, Quantification of endothelial proliferation after stretch in in YAP, TAZ, YAP/TAZ and VE-Cadherin knockdown cells and control. HUVECs were subjected to cyclic stretch for 24h and percentage of cells**
in S phase was determined by EdU pulsing and immunofluorescence staining. Graph shows the mean ±
SD fold change in percentage of S phase positive cells of stretched to non stretched cells for each
knockdown condition. n= 5 independent experiments, > 100 cells counted per experiment per condition.

Figure 3 – Figure supplement 1. YAP and TAZ proteins are lost after gene knockdown by siRNA
in HUVECs.
HUVECs were treated with non targeting siRNA (siCTR) or siRNA targeting YAP, TAZ and YAP +TAZ
for 24h. A-H, Immunofluorescence staining for YAP (green, A-D) or TAZ (green, E-H) and labelling of
nuclei with DAPI (magenta) 72h after siRNA transfection. Scale bar: 10μm. I, Western blot for YAP/TAZ
and GAPDH 72h after siRNA transfection.

Figure 3 – Figure supplement 2. VEGF treatment does not affect YAP and TAZ subcellular
localisation.
A-H, Confluent HUVECs were treated with 40ng/mL of VEGF for 30 min (B, F), 1h (C,G) and 3h (D,H)
or control (A,E) and stained for YAP (A-D) or TAZ (E-H) and DAPI (not shown). I,J, Quantification of
nuclear to cytoplasmic ratio of YAP (I) or TAZ (J) with VEGF treatment of one representative
experiment. Nuclear/cytoplasmic ratio > 1, YAP/TAZ nuclear; nuclear/cytoplasmic ratio < 1, YAP/TAZ
cytoplasmic. At least 200 cells quantified per condition per experiment. n= 2 independent experiments.

Figure 4. Combined loss of YAP and TAZ leads to decreased sprouting numbers and shape
defects, vessel crosses, haemorrhages at the sprouting front and adherens junctions’ defects in
vivo.
A, B, P6 retinal vessels labelled with IB4 (green) and stained for ERG (magenta, marking endothelial
nuclei) in YapTaz iEC-KO (B) and littermate control mice (A). Yellow asterisks mark sprouts. A’,B’;
magnification of boxed areas in A and B. n=9 control/9 KO pups. Scale bar: A,B 100μm, A’, B’ 25μm.
C, D, P6 retinal vessels labelled with IB4 in YapTaz iEC-KO (D) and littermate control mice (E). Red
arrowheads, vessel crosses. C’, D’, magnification of boxed areas in C,D. C’’,D’’, depiction of vessels in
C’ and D’; different colours represent vessels in different 3D planes. n=4 control/4 KO pups. Scale bar:
C,D 100μm, C’-D’ 20μm.
E, F, P6 retinal vessels labelled with IB4 (green) and stained for TER119 (magenta, marking red blood
cells) in YapTaz iEC-KO (F) and littermate control mice (E). Red arrowheads, haemorrhages. E’,F’;
magnification of boxed areas in E and F. n=4 control/5 KO pups. Scale bar: E,F 1000μm, E’, F’ 100μm.
G, H, P6 retinal vessels labelled with IB4 (green) and stained for VE-Cadherin (magenta) in YapTaz iEC-KO (H) and littermate control mice (G). Red arrowheads, no longitudinal VE-Cadherin labelled junction along vessel axis denoting unicellular vessel segments. G',H', G'',H'', magnification of boxed areas in G and H. n=4 control/4 KO pups. Scale bar: G,H 25μm, G',H' 5μm, G'',H'' 10μm.

Figure 4 - Figure supplement 1. Combined loss of YAP and TAZ leads to decreased number of sprouts in the developing mouse retina.
Quantification of number of sprouts per 100 μm of sprouting front extension at P6 in YapTaz iEC-KO (n=9 pups) and littermate control mice (n=9 pups). Data are mean +/- SD. p values were calculated using unpaired t-test. *, p<0.05.

Figure 5. YAP and TAZ regulate adherens junctions’ morphology, monolayer permeability and VE-Cadherin turnover in vitro.
A-D, HUVECs knocked down for YAP (B), TAZ (C) and YAP/TAZ (D) and control (A) stained for VE-Cadherin. Red arrowheads, discontinuous VE-Cadherin. Scale bar: 50μm. E, Representative patches used for manual morphological classification of adherens junctions in 5 categories: straight junctions, thick junctions, thick to reticular junctions, reticular junctions and fingers. F, Morphological analysis of VE-Cadherin labelled cell junctions in HUVECs knocked down for YAP, TAZ and YAP/TAZ. Data are mean percentage ± SD of 3 independent experiments (2 for siTAZ). n> 140 patches of VE-Cadherin stained HUVECs per knockdown condition per experiment. p values were calculated using unpaired t-test between knocked down cells for YAP, TAZ and YAP/TAZ and control. *, p<0.05; **, p<0.01.
G, Permeability of YAP, TAZ and YAP/TAZ knockdown monolayers of HUVECs to 250kDa fluorescent dextran molecules. Data are mean ± SD of 3 independent experiments. p values were calculated using unpaired t-test between knocked down cells for YAP, TAZ and YAP/TAZ and control. RFU, relative fluorescence units. *, p<0.05.
H, I, HUVECs knocked down for YAP/TAZ (I) and control (H) triple labelled with DAPI (blue), pulsed VE-Cadherin 55-7HI (red, VE-Cadherin pulse), and surface VE-Cadherin (green, VE-Cadherin staining). VE-Cadherin 55-7HI pulse was done for 30 minutes and cells were fixed 2 hours after end of pulse. Scale bar: 20μm. J, Representative patches used for manual classification of junctions into high, intermediate and low turnover. K, Quantification of junctional turnover in YAP/TAZ knockdown cells and control. L, Quantification of the percentage of high turnover junctions in each morphological category in YAP/TAZ knockdown cells and control. K, L, Data are mean ± SD of 3 independent experiments. n> 70 patches per knockdown condition per experiment. Fewer then 5 patches were reticular in YAP/TAZ
knockdown, not allowing for reliable assessment of percentages between high, intermediate and low turnover. *p values were calculated using unpaired t-test. *, \( p<0.05 \).

**M, N.** Fluorescence loss after photoconversion of VE-Cadherin mEos in straight junctions of YAP/TAZ knockdown HUVECs and control HUVECs. M, VE-Cadherin mEos immobile fraction. N, VE-Cadherin mEos half-life of fluorescence loss. Data are mean ± SD of 3 independent experiments. n= 15 control cells and 16 cells YAP/TAZ knockdown cells. *p values were calculated using unpaired t-test between knocked down cells for YAP/TAZ and control. **, \( p<0.01 \).

O, P, HUVECs knocked down for YAP/TAZ (P) and control (O) double stained for VE-Cadherin (red) and f-actin (green, phalloidin). O’, P’, f-actin (black, phalloidin). Scale bar: 50μm.

**Figure 5 - Supplementary video 1. Reticular junctions correspond to junction associated intermediate lamellipodia.**

Live imaging of VE-Cadherin-EGFP expressing HUVECs. Reticular junctions were identified as junction associated intermediate lamellipodia from their common outline shape. Thick to reticular junctions correspond to small junction associated intermediate lamellipodia. Scale bar 20μm.

**Figure 6. YAP and TAZ are required for uncoupled, individual cell migration.**

A-H, Phase contrast images of YAP (C,D), TAZ (E,F) and YAP/TAZ (G,H) knockdown HUVECs and control (A,B) immediately after removing barrier to create a cell free space (A,C,E,G) and 16 hours later (B,D,F,H). I, Quantification of wound closure at 16 hours. Data are mean +/- SD of 3 independent experiments (8-9 biological replicates). *p values were calculated using unpaired t-test between knocked down cells for YAP, TAZ or YAP/TAZ and control. ****, \( p<0.0001 \).

J, K, Phase contrast images of YAP/TAZ knockdown monolayer of HUVECs (K) and control (J). L, M, Fluorescence labelling of nuclei with DAPI of YAP/TAZ knockdown monolayer of HUVECs (M) and control (L). Scale bar: 100mm. L’,M’, Longest axis of nuclei. N, Alignment score between nuclei pairs used for quantification of cell coordination in O. Angles made by the nuclei longest axis of a pair of nuclei were calculated; angles of 0, 45 and 90 degrees scored 1,0 and -1 in alignment. O, Coordination plot of monolayers of HUVECs knocked down for YAP, TAZ and YAP and TAZ and control. Graph shows mean alignment score of all pairs of cells in the monolayer plotted against distance between them. Randomly aligned cells score 0 in mean alignment. n= 3 independent experiments, >10.000 pairs of nuclei analysed per knockdown condition per experiment.

**Figure 7. Nuclear YAP and TAZ inhibit Notch and BMP signalling in endothelial cells.**
A-B, Retinas from P6 Taz iEC-GOF (B) and control pups (A) were stained for the endothelial marker PECAM (blue) and the endothelial nuclei marker ERG (red). Taz iEC-GOF mice express mosaically nuclear EGFP (nEGFP, green) marking cells expressing the TAZ gain of function mutation TAZS89A. Yellow asterisks mark sprouts. Images correspond to maximum projection of z stack. Scale bar: 50μm.

C, Quantification of number of sprouts per 100μm of sprouting front extension at P6 in Taz iEC-GOF mice (n= 6 pups) and littermate control mice (n=6 pups). Data are mean +/- SD. p values were calculated using unpaired t-test. **, p<0.01.

D, Quantification of branching frequency (i.e. number of branching points per field of view) in Taz iEC-GOF mice (n= 6 pups) and littermate control mice (n=6 pups). Data are mean +/- SD. p values were calculated using unpaired t-test. **, p<0.01.

E, Reverse transcriptase PCR of HUVECs transduced with adenoviruses carrying YAP (AdYAP) and TAZ (AdTAZ) constitutively active forms and control (AdGFP). Data are mean +/- SD of 3 independent experiments. p values were calculated using unpaired t-test between AdGFP and AdYAP or AdTAZ. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.

F, Reverse transcriptase PCR of YAP/TAZ knockdown HUVECs and control. Data are mean +/- SD of 3 independent experiments. p values were calculated using unpaired t-test. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.

G,H, P6 retinal vessels labelled with IB4 (green) and stained for DLL4 (magenta) in YapTaz iEC-KO (H) and littermate control mice (G). Images correspond to maximum projection of z stack. Scale bar: 50μm.

I,J, P6 retinal vessels labelled with IB4 (blue) and stained for ERG (red, marking endothelial nuclei) and pSMAD1/5/8 (green) in YapTaz iEC-KO (J) and littermate control mice (I). Images correspond to single confocal planes. I',J', magnification of boxed areas in I and J. Red arrowheads, endothelial nuclei negative for pSMAD1/5/8. Green arrowheads, endothelial nuclei positive for pSMAD1/5/8. Scale bar: I,J 50μm, I', J' 10μm.

K, Quantification of endothelial cells positive for pSMAD1/5/8 at the sprouting front of the P6 retina in YapTaz iEC-KO (n= 3 pups) and littermate control mice (n=3 pups). Data are mean percentage +/- SD. p values were calculated using unpaired t-test. ****, p<0.0001.

Figure 7 - Figure supplement 1. Targeting strategy used for the generation of the conditional TAZ gain-of-function mouse model.

cDNA coding for a 3xFLAG-tagged human TAZ S89A was inserted into a Rosa26 targeting vector downstream of the ubiquitous CAG promoter. The cDNA also included an internal ribosome entry sequence (IRES) and a nuclear-localized enhanced green fluorescence protein (nEGFP) for monitoring transgene expression. To allow Cre-dependent expression of 3xFLAG-TAZS89A and of the EGFP
reporter, a floxed transcriptional STOP cassette was incorporated between the 3xFLAG-TAZS89A-
IRES-nEGFP sequence and the CAG promoter.

**Figure 7 - Figure supplement 2. Microarray of YAP and TAZ gain of function mutant cells.**

Heatmaps of Notch, BMP and Hippo pathway genes in control (AdGFP), AdYAP and AdTAZ HUVECs.

**Figure 7 - Figure supplement 3. YAP and TAZ knockdown increases Notch and BMP reporter activities in vitro.**

A-C, Luciferase reporter assays in YAP, TAZ and YAP/TAZ knockdown HUVECs and controls for Notch reporter (A), BMP reporter (B) and TEAD reporter (C). Data are mean +/- SD. *p values were calculated using unpaired t-test. n ≥ 3 experiments for Notch reporter, 3 experiments for BMP reporter, ≥ 6 experiments for TEAD reporter. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.

**Figure 7 - Figure supplement 4. DLL4 intensity in YapTaz iEC-KO.**

Graph shows mean DLL4 staining intensity in the vascular retina of control (green) and YapTaz iEC-KO (red) P6 pups normalised to the background intensity. Data are mean +/- SEM. n= 3 control and 3 YapTaz iEC-KO.

**Figure 8. BMP inhibition partially rescues the cellular defects of YAPTAZ knockdown HUVECs.**

A, Luciferase reporter assay for Notch activity in YAP/TAZ knockdown HUVECs and controls treated with 0.1μM DBZ or DMSO. Data are mean +/- SEM. *p values were calculated using unpaired t-test. n≥3 biological replicates.

B, Quantification of wound closure at 16h for HUVECs knocked down for YAP/TAZ and treated with 0.1μM DBZ or DMSO. Data are mean +/- SD. *p values were calculated using unpaired t-test. n = 6 biological replicates.

C, Schematic of the BMP inhibitors used depicting preferential sites of inhibition. Alk1fc, ENGecd and Gremlin preferentially bind extracellular BMPs. K02288 and Ldn193189 are kinase inhibitors.

D, Luciferase reporter assay for BMP activity in YAP/TAZ knockdown HUVECs and controls treated with 25 ng/mL Alk1fc, 0.25μg/mL ENGecd, 0.1μg/mL Gremlin, 1μM K02288, 1μM Ldn193189 and DMSO. Data are mean +/- SEM. *p values were calculated using unpaired t-test. n≥3 biological replicates.

E, Quantification of wound closure at 16h for HUVECs knocked down for YAP/TAZ and treated with 1μM Ldn193189 or DMSO. Data are mean +/- SD. *p values were calculated using unpaired t-test. n = 6-7 biological replicates.
F, Permeability of HUVECs knocked down for YAP/TAZ and treated with 1μM Ldn193189 or DMSO to 250kDa fluorescent dextran molecules. Data are mean +/- SD. RFU, relative fluorescence units. p values were calculated using unpaired t-test. n = 6 biological replicates.


I, Morphological analysis of VE-Cadherin labelled cell junctions in HUVECs knocked down for YAP/TAZ and treated with 1μM Ldn193189 or DMSO control. Data are mean ± SD. p values were calculated using unpaired t-test. n= 3 biological replicates; n≥ 45 patches of VE-Cadherin stained HUVECs per condition per replicate.

Figure 8 - Figure supplement 1. Nuclear YAP and TAZ increase the expression of BMP inhibitors. Heatmap of BMPs, BMP receptors and co-receptors and BMP inhibitors genes in control (AdGFP), AdYAP and AdTAZ gain of function mutant cells.

Supplementary File 1. List of reagents used to manipulate Notch and BMP signaling in cell culture.

Supplementary File 2. List of primary antibodies and dyes used.

Supplementary File 3. List of the TaqMan primers (Applied Biosystems) used.

Source code file 1. Mouse retina regularity script. Determines the regularity of the gaps in the mouse retina vasculature Used in figure 2 r, K, L. Written in Python.

Source code file 2. VE-Cadherin turnover analysis script. Used in figure 5 K, L. Written in Python.


Source code file 4. Cell coordination analysis script. Segments images of DAPI stained cell nuclei in a confluent monolayer and assesses the alignment between cells as a function of their distance. Used in figure 6 N, O. Written in Python.

Source code file 5. Dll4 gradient analysis script. Analyses Dll4 intensity in the mouse retina as a function of the distance to the sprouting front. Used in figure 7 – figure supplement 4. Written in Python.
**Figure 2** – source data. Values for quantification of radial expansion (Figure 2G), vessel density (Figure 2H), branching frequency (Figure 2I), area of gaps (Figure 2J) and standard deviation of area (Figure 2K) and circularity (Figure 2L) of gaps in P6 Yap iEC-KO, Taz iEC-KO and YapTaz iEC-KO and respective control pups. Each value corresponds to the average of several measurements for one animal (see material and methods for details).

**Figure 3** – source data. Values for quantification of endothelial proliferation (Figure 3C) and apoptosis (Figure 3F) in P6 Yap iEC-KO, Taz iEC-KO and YapTaz iEC-KO and respective control pups. Each value corresponds to the average of several measurements for one animal (see material and methods for details).

Values for quantification of endothelial proliferation in vitro in response to VEGF (Figure 3G) and stretch (Figure 3H) in YAP, TAZ and YAPTAZ knockdown cells.

**Figure 5** - source data. Values for quantification of morphological (Figure 5F) and junctional turnover (Figure 5K) analysis of VE-Cadherin in HUVECs knocked down for YAP, TAZ and YAP/TAZ. Values for quantification of permeability of YAP, TAZ and YAP/TAZ knockdown monolayers of HUVECs to 250kDa fluorescent dextran molecules (Figure 5G). Values for quantification of VE-Cadherin mEos immobile fraction (Figure 5M) and half-life of fluorescence loss (Figure 5N).

**Figure 6** - source data. Values for quantification of wound closure at 16 hours in YAP, TAZ and YAP/TAZ knockdown HUVECs and control (Figure 6I).

**Figure 7** - source data. Values for quantification of number of sprouts (Figure 7C) and branching frequency (Figure 7D) in Taz iEC-GOF mice and controls. RT-PCR values of YAP and TAZ gain of function (Figure 7E) and loss of function (Figure 7F) HUVECs for Notch and BMP genes. Values for quantification of pSMAD1/5/8 staining in P6 retinas of YapTaz iEC-KO (Figure 7K).

**Figure 8** - source data. Values of luciferase reporter assays for Notch (Figure 8A) and BMP (Figure 8D) activity in YAP/TAZ knockdown HUVECs and controls treated with Notch or BMP inhibitors. Values for quantification of wound closure at 16 hours in YAP/TAZ knockdown HUVECs treated with Notch (Figure 8B) and BMP (Figure 8E) inhibitors. Values for quantification of permeability of YAP/TAZ knockdown HUVECs treated with 1μM Ldn193189 (Figure 8F). Values for quantification of
morphological analysis of VE-Cadherin in YAP/TAZ knockdown HUVECs treated with 1μM Ldn193189 (Figure 8I).
Figure 1. YAP and TAZ are expressed throughout the vasculature of developing mouse retinas, and localise to the nucleus of sprouting endothelial cells.

Immunofluorescence staining of YAP (green, A-D and A’-D’) and TAZ (green, E-H and E’-H’) was performed in wild-type mouse retinas at post-natal day 6 (P6). Retinas were co-stained with the endothelial membrane marker Isolectin-B4 (IB4; blue) and with antibodies against the endothelial nuclei marker ERG (red). White dotted lines, outline of endothelial nuclei. Yellow dotted lines, outline of perivascular cells’ nuclei. Green arrowheads, nuclear localisation of YAP and TAZ. Red arrowheads, cytoplasmic localisation of YAP and TAZ. Yellow arrowheads, junctional localisation of YAP and TAZ. Images correspond to single confocal planes. n>3 animals for each staining. Scale bar: 10μm.
Figure 1 - Figure supplement 1. YAP and TAZ localise at endothelial adherens junctions in the mouse retina.

Immunofluorescence stainings of YAP (green, A-C, A'-C'), TAZ (green, D-F, D'-F') and VE-Cadherin (red, B,E,B',E') were performed in wild-type mouse retinas at P6. Arrows, co-localisation of YAP or TAZ with VE-Cadherin. Images correspond to single confocal planes. n> 3 pups per staining. Scale bar A-C and D-F 10μm, A'-C' and D'-F' 3μm.
Figure 2

(A-F) Retinas from P6 Yap iEC-KO (B), Taz iEC-KO (D) and YapTaz iEC-KO (F), and respective control pups (A,C,E) were stained with Isolectin B4 (IB4). Scale bar: 200μm.

(G-J) Quantification of radial expansion (G), vessel density (H), branching frequency (I) in Yap iEC-KO, Taz iEC-KO and YapTaz iEC-KO retinas. Results are shown as percentage of the respective controls. Data are mean +/- SD. n≥ 5 pups. p values were calculated using unpaired t-test. *, p<0.05; **, p<0.01; ****, p<0.0001.

(K-L) Quantification of the standard deviation of the area (K) and circularity (L) of the vessels loops in Yap iEC-KO, Taz iEC-KO and YapTaz iEC-KO retinas. Results are shown as percentage of the respective controls. Data are mean +/- SD. n≥ 5 pups. p values were calculated using unpaired t-test. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.

Figure 2 – Endothelial YAP and TAZ are required for vessel growth, branching and homogeneity of the plexus

(A-F) Retinas from P6 Yap iEC-KO (B), Taz iEC-KO (D) and YapTaz iEC-KO (F), and respective control pups (A,C,E) were stained with Isolectin B4 (IB4). Scale bar: 200μm.

(G-J) Quantification of radial expansion (G), vessel density (H), branching frequency (I) in Yap iEC-KO, Taz iEC-KO and YapTaz iEC-KO. Results are shown as percentage of the respective controls. Data are mean +/- SD. n≥ 5 pups. p values were calculated using unpaired t-test. *, p<0.05; **, p<0.01; ****, p<0.0001.

(K-L) Quantification of the standard deviation of the area (K) and circularity (L) of the vessels loops in Yap iEC-KO, Taz iEC-KO and YapTaz iEC-KO retinas. Results are shown as percentage of the respective controls. Data are mean +/- SD. n≥ 5 pups. p values were calculated using unpaired t-test. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.
Figure 2 – Figure supplement 1. YAP and TAZ proteins are lost upon Cre-mediated genetic deletion in P6 mouse retinas.

Yap iEC-KO (Yap\textsuperscript{fl/fl} Pdgfb-iCreERT2\textsuperscript{+/wt}), Taz iEC-KO (Taz\textsuperscript{fl/fl} Pdgfb-iCreERT2\textsuperscript{+/wt}) and respective littermate control mice (Yap\textsuperscript{Control}, Yap\textsuperscript{fl/fl} and Taz\textsuperscript{Control}, Taz\textsuperscript{fl/fl}) were injected with tamoxifen at P1 and P3. At P6, mouse retinas were stained for YAP (grey, B,D), TAZ (grey, F,H), and with Isolectin B4 (IB4; red, A,C,E,G). n> 3 pups. Scale bar: 20μm.
Figure 2 – Figure supplement 2. TAZ compensates for the loss of YAP in endothelial cells in vivo.
Retinas from P6 Yap iEC-KO (B,D and B',D') and littermate controls (A,C and A', C') were immunostained for TAZ. Green arrowheads, nuclear Taz. A,B, A',B' images correspond to maximum projection of z stack. C,D,C',D' correspond to single confocal planes. n> 3 pups. Scale bar: A-D 50μm, A'-D' 20μm.
Figure 3. YAP and TAZ are required for endothelial cell proliferation in vivo and endothelial cell proliferation in response to mechanical stretch in vitro.

A,B. P6 retinal vessels labelled with IB4 (grey) and stained for EdU (red, marking S phase positive cells) and Erg (green, marking endothelial nuclei) in YapTaz iEC-KO (B) and littermate control mice (A). A', B', mask of Erg + cells indicating endothelial nuclei. A'', B'', mask of Erg + and EdU + cells indicating proliferating endothelial cells. C. Quantification of endothelial proliferation in Yap iEC-KO (n=3 control/4 KO pups), Taz iEC-KO (n=5 control/5 KO pups) and YapTaz iEC-KO (n=8 control/7 KO pups). Number of EdU-positive and ERG-positive cells per IB4 labelled vascular area was calculated for each genotype and results are shown in percentage of the respective controls. Data are mean +/- SD. p values were calculated using unpaired t-test. ns, p>0.05; *, p<0.05; **, p<0.01. Scale bar: 50μm.

D,E. P6 retinal vessels labelled with IB4 (grey) and stained for cleaved caspase 3 (red) in YapTaz iEC-KO (E) and littermate control mice (D). D', E', magnification of boxed area in D,E. Red arrowheads, cleaved caspase 3 positive endothelial cell. Black arrowheads, cleaved caspase 3 outside vessels. D'', E'', mask of cleaved caspase 3 positive endothelial cells. F. Quantification of endothelial apoptosis in Yap iEC-KO (n=7 control/7 KO pups), Taz iEC-KO (n=4 control/4KO pups) and YapTaz iEC-KO (n=5 control/4 KO pups). Data are mean +/- SD. p values were calculated using unpaired t-test. ns, p>0.05. Scale bar: D-E 100μm, D'-E' 50μm.

G. Quantification of endothelial proliferation with increasing concentrations of VEGF treatment in YAP, TAZ and YAP/TAZ knockdown cells and control. HUVECs were treated with 0, 40, 200 or 1000 ng/mL VEGF for 24h and the percentage of cells in S phase was determined by flow cytometry. Graph shows the mean + SD fold change in percentage of S phase positive cells relative to 0 ng/mL of VEGF treatment. n= 3 independent experiments; > 50.000 cells analysed per experiment per condition.

H. Quantification of endothelial proliferation after stretch in YAP, TAZ, YAP/TAZ and VE-Cadherin knockdown cells and control. HUVECs were subjected to cyclic stretch for 24h and percentage of cells in S phase was determined by EdU pulsing and immunofluorescence staining. Graph shows the mean + SD fold change in percentage of S phase positive cells of stretched to non stretched cells for each knockdown condition. n= 5 independent experiments, > 100 cells counted per experiment per condition. p values were calculated using unpaired t-test. ns, p>0.05; *, p<0.05.
Figure 3 – Figure supplement 1

HUVECs were treated with non targeting siRNA (siCTR) or siRNA targeting YAP, TAZ and YAP + TAZ for 24h. A-H, Immunofluorescence staining for YAP (green, A-D) or TAZ (green, E-H) and labelling of nuclei with DAPI (magenta) 72h after siRNA transfection. Scale bar: 10μm. I, Western blot for YAP/TAZ and GAPDH 72h after siRNA transfection.
Figure 3 – Figure supplement 2. VEGF treatment does not affect YAP and TAZ subcellular localisation. Confluent HUVECs were treated with 40ng/mL of VEGF for 30 min (B, F), 1h (C,G) and 3h (D,H) or control (A,E) and stained for YAP (A-D) or TAZ (E-H) and DAPI (not shown). I, J, Quantification of nuclear to cytoplasmic ratio of YAP (I) or TAZ (J) with VEGF treatment of one representative experiment. Nuclear/cytoplasmic ratio > 1, YAP/TAZ nuclear; nuclear/cytoplasmic ratio < 1, YAP/TAZ cytoplasmic. At least 200 cells quantified per condition per experiment. n= 2 independent experiments.
Figure 4. Combined loss of YAP and TAZ leads to decreased sprouting numbers and shape defects, vessel crosses, haemorrhages at the sprouting front and adherens junctions’ defects in vivo.

A,B, P6 retinal vessels labelled with IB4 (green) and stained for ERG (magenta, marking endothelial nuclei) in YapTaz iEC-KO (B) and littermate control mice (A). Yellow asterisks mark sprouts. A’,B’, magnification of boxed areas in A and B. n=9 control/9 KO pups. Scale bar: A,B 100 μm, A’, B’ 25 μm.

C,D, P6 retinal vessels labelled with IB4 in YapTaz iEC-KO (D) and littermate control mice (E). Red arrowheads, vessel crosses. C’, D’, magnification of boxed areas in C,D. C”’, D”’, depiction of vessels in C’ and D’. Different colours represent vessels in different 3D planes. n=4 control/4 KO pups. Scale bar: C,D 100 μm, C”’, D”’ 20 μm.

E,F, P6 retinal vessels labelled with IB4 (green) and stained for TER119 (magenta, marking red blood cells) in YapTaz iEC-KO (F) and littermate control mice (E). Red arrowheads, haemorrhages. E’,F’, magnification of boxed areas in E and F. n=4 control/5 KO pups. Scale bar: E,F 1000 μm, E’, F’ 100 μm.

G,H, P6 retinal vessels labelled with IB4 (green) and stained for VE-Cadherin (magenta) in YapTaz iEC-KO (H) and littermate control mice (G). Red arrowheads, no longitudinal VE-Cadherin labelled junction along vessel axis denoting unicellular vessel segments. G’,H’, G”’, H”’, magnification of boxed areas in G and H. n=4 control/4 KO pups. Scale bar: G,H 25 μm, G’,H’ 5 μm, G”’, H”’ 10 μm.
Figure 4 - Figure supplement 1. Combined loss of YAP and TAZ leads to decreased number of sprouts in the developing mouse retina.
Quantification of number of sprouts per 100 μm of sprouting front extension at P6 in YapTaz iEC-KO (n= 9 pups) and littermate control mice (n=9 pups). Data are mean +/- SD. p values were calculated using unpaired t-test. *, p<0.05.
Figure 5. YAP and TAZ regulate adherens junctions' morphology, monolayer permeability and VE-Cadherin turnover in vitro.

A-D. HUVECs knocked down for YAP (B), TAZ (C) and YAP/TAZ (D) and control (A) stained for VE-Cadherin. Red arrowheads, discontinuous VE-Cadherin. Scale bar: 50μm. E. Representative patches used for manual morphological classification of adherens junctions in 5 categories: straight junctions, thick junctions, thick to reticular junctions, reticular junctions and fingers. F. Morphological analysis of VE-Cadherin labelled cell junctions in HUVECs knocked down for YAP, TAZ and YAP/TAZ. Data are mean percentage ± SD of 3 independent experiments. *, p<0.05; **, p<0.01.

G. Permeability of YAP, TAZ and YAP/TAZ knockdown monolayers of HUVECs to 250kDa fluorescent dextran molecules. Data are mean ± SD of 3 independent experiments. p values were calculated using unpaired t-test between knocked down cells for YAP, TAZ and YAP/TAZ and control. *, p<0.05; **, p<0.01.

H, I. HUVECs knocked down for YAP/TAZ (I) and control (H) triple labelled with DAPI (blue), pulsed VE-Cadherin 55-7HI (red, VE-Cadherin pulse), and surface VE-Cadherin (green, VE-Cadherin staining). VE-Cadherin 55-7HI pulse was done for 30 minutes and cells were fixed 2 hours after end of pulse. Scale bar: 20μm. J. Representative patches used for manual classification of junctions into high, intermediate and low turnover. K. Quantification of junctional turnover in YAP/TAZ knockdown cells and control. L. Quantification of the percentage of high turnover junctions in each morphological category in YAP/TAZ knockdown cells and control. K, L. Data are mean ± SD of 3 independent experiments. n> 70 patches per knockdown condition per experiment. Fewer then 5 patches were reticular in YAP/TAZ knockdown, not allowing for reliable assessment of percentages between high, intermediate and low turnover. p values were calculated using unpaired t-test. *, p<0.05.

M, N. Fluorescence loss after photoconversion of VE-Cadherin mEos in straight junctions of YAP/TAZ knockdown HUVECs and control HUVECs. M. VE-Cadherin mEos immobile fraction. N. VE-Cadherin mEos half-life of fluorescence loss. Data are mean ± SD of 3 independent experiments. n=15 control cells and 16 cells YAP/TAZ knockdown cells. p values were calculated using unpaired t-test between knocked down cells for YAP/TAZ and control. **, p<0.01.

O, P. HUVECs knocked down for YAP/TAZ (P) and control (O) double stained for VE-Cadherin (red) and f-actin (green, phalloidin). O'. P', f-actin (black, phalloidin). Scale bar: 50μm.
Figure 6. YAP and TAZ are required for uncoupled, individual cell migration.

A-H, Phase contrast images of YAP (C,D), TAZ (E,F) and YAP/TAZ (G,H) knockdown HUVECs and control (A,B) immediately after removing barrier to create a cell free space (A,C,E,G) and 16 hours later (B,D,F,H). I, Quantification of wound closure at 16 hours. Data are mean +/- SD of 3 independent experiments (8-9 biological replicates). *p values were calculated using unpaired t-test between knocked down cells for YAP, TAZ or YAP/TAZ and control. ****, p<0.0001.

J,K, Phase contrast images of YAP/TAZ knockdown monolayer of HUVECs (K) and control (J). Longest axis of nuclei. L, Fluorescence labelling of nuclei with DAPI of YAP/TAZ knockdown monolayer of HUVECs (M) and control (L). Scale bar: 100 μm. L’,M’. Longest axis of nuclei.

N, Alignment score between nuclei pairs used for quantification of cell coordination in O. Angles made by the nuclei longest axis of a pair of nuclei were calculated; angles of 0, 45 and 90 degrees scored 1, 0 and -1 in alignment.

O, Coordination plot of monolayers of HUVECs knocked down for Yap, Taz and Yap and Taz and control. Graph shows mean alignment score of all pairs of cells in the monolayer plotted against distance between them. Randomly aligned cells score 0 in mean alignment. n= 3 independent experiments, >10,000 pairs of nuclei analysed per knockdown condition per experiment.
Figure 7. Nuclear YAP and TAZ inhibit Notch and BMP signalling in endothelial cells.
A-B, Retinas from P6 Taz iEC-GOF (B) and control pups (A) were stained for the endothelial marker PECAM (blue) and the endothelial nuclei marker ERG (red). Taz iEC-GOF mice express mosaically nuclear EGFP (nEGFP, green) marking cells expressing the TAZ gain of function mutation TAZS89A. Yellow asterisks mark sprouts. Images correspond to maximum projection of z stack. Scale bar: 50 μm.

C, Quantification of number of sprouts per 100 μm of sprouting front extension at P6 in Taz iEC-GOF mice (n= 6 pups) and littermate control mice (n=6 pups). Data are mean +/- SD. p values were calculated using unpaired t-test. **, p<0.01.

D, Quantification of branching frequency (i.e. number of branching points per field of view) in Taz iEC-GOF mice (n= 6 pups) and littermate control mice (n=6 pups). Data are mean +/- SD. p values were calculated using unpaired t-test. **, p<0.01.

E, Reverse transcriptase PCR of HUVECs transduced with adenoviruses carrying YAP (AdYAP) and TAZ (AdTAZ) constitutively active forms and control (AdGFP). Data are mean +/- SD of 3 independent experiments. p values were calculated using unpaired t-test between AdGFP and AdYAP or AdTAZ. *, p<0.05; **, p<0.01; ***p<0.001; ****p<0.0001.

F, Reverse transcriptase PCR of YAP/TAZ knockdown HUVECs and control. Data are mean +/- SD of 3 independent experiments. p values were calculated using unpaired t-test. *, p<0.05; **, p<0.01; ***p<0.001; ****p<0.0001.

G,H, P6 retinal vessels labelled with IB4 (green) and stained for DLL4 (magenta) in YapTaz iEC-KO mice (H) and littermate control mice (G). Images correspond to maximum projection of z stack. Scale bar: 50μm.

I,J, P6 retinal vessels labelled with IB4 (blue) and stained for ERG (red, marking endothelial nuclei) and pSMAD1/5/8 (green) in YapTaz iEC-KO (J) and littermate control mice (I). Images correspond to single confocal planes. I’,J’, magnification of boxed areas in I and J. Red arrowheads, endothelial nuclei negative for pSMAD1/5/8. Green arrowheads, endothelial nuclei positive for pSMAD1/5/8. Scale bar: I,J 50μm, I’, J’ 10μm.

K, Quantification of endothelial cells positive for pSMAD1/5/8 at the sprouting front of the P6 retina in YapTaz iEC-KO (n= 3 pups) and littermate control mice (n=3 pups). Data are mean percentage +/- SD. p values were calculated using unpaired t-test. ****, p<0.0001.
cDNA coding for a 3xFLAG-tagged human TAZ S89A was inserted into a Rosa26 targeting vector downstream of the ubiquitous CAG promoter. The cDNA also included an internal ribosome entry sequence (IRES) and a nuclear-localized enhanced green fluorescence protein (nEGFP) for monitoring transgene expression. To allow Cre-dependent expression of 3xFLAG-TAZS89A and of the EGFP reporter, a floxed transcriptional STOP cassette was incorporated between the 3xFLAG-TAZS89A-IRES-nEGFP sequence and the CAG promoter.
Figure 7 - Figure Supplement 2. Microarray of YAP and TAZ gain of function mutant cells.
Heatmaps of Notch, BMP and Hippo pathway genes in control (AdGFP), AdYAP and AdTAZ HUVECs.
Figure 7 - Figure supplement 3. YAP and TAZ knockdown increases Notch and BMP reporter activities in vitro.

A-C. Luciferase reporter assays in YAP, TAZ and YAP/TAZ knockdown HUVECs and controls for Notch reporter (A), BMP reporter (B) and TEAD reporter (C). Data are mean +/- SD. * values were calculated using unpaired t-test. n ≥ 3 experiments for Notch reporter, 3 experiments for BMP reporter, ≥ 6 experiments for TEAD reporter. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.
Figure 7 - Figure Supplement 4. DLL4 intensity in YapTaz iEC-KO. Graph shows mean DLL4 staining intensity in the vascular retina of control (green) and YapTaz iEC-KO (red) P6 pups normalised to the background intensity. Data are mean +/- SEM. n= 3 control and 3 YapTaz iEC-KO.
Figure 8. BMP inhibition partially rescues the cellular defects of YAP/TAZ knockdown HUVECs.

A. Luciferase reporter assay for Notch activity in YAP/TAZ knockdown HUVECs and controls treated with 0.1 μM DBZ or DMSO. Data are mean +/- SEM. p values were calculated using unpaired t-test. n ≥ 3 biological replicates.

B. Quantification of wound closure at 16h for HUVECs knocked down for YAP/TAZ and treated with 0.1 μM DBZ or DMSO. Data are mean +/- SEM. p values were calculated using unpaired t-test. n = 6 biological replicates.

C. Schematic of the BMP inhibitors used depicting preferential sites of inhibition. Alk1-fc, ENG-ecd and Gremlin preferentially bind extracellular BMPs. K02288 and Ldn193189 are kinase inhibitors.

D. Luciferase reporter assay for BMP activity in YAP/TAZ knockdown HUVECs and controls treated with 25 ng/mL Alk1-fc, 0.25 μg/mL ENG-ecd, 0.1 μg/mL Gremlin, 1 μM K02288, 1 μM Ldn193189 and DMSO. Data are mean +/- SEM. p values were calculated using unpaired t-test. n ≥ 3 biological replicates.

E. Quantification of wound closure at 16h for HUVECs knocked down for YAP/TAZ and treated with 1 μM Ldn193189 or DMSO. Data are mean +/- SD. p values were calculated using unpaired t-test. n = 6-7 biological replicates.

F. Permeability of HUVECs knocked down for YAP/TAZ and treated with 1 μM Ldn193189 or DMSO to 250kDa fluorescent dextran molecules. Data are mean +/- SD. RFU, relative fluorescence units. p values were calculated using unpaired t-test. n = 6 biological replicates.


I. Morphological analysis of VE-Cadherin labelled cell junctions in HUVECs knocked down for YAP/TAZ and treated with 1 μM Ldn193189 or DMSO control. Data are mean ± SD. p values were calculated using unpaired t-test. n = 3 biological replicates; n ≥ 45 patches of VE-Cadherin stained HUVECs per condition per replicate.
Figure 8 - Figure Supplement 1. Nuclear YAP and TAZ increase the expression of BMP inhibitors
Heatmap of BMPs, BMP receptors and co-receptors and BMP inhibitors genes in control (AdGFP), AdYAP and AdTAZ gain of function mutant cells.